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INTRODUCTION 
Neonatal hyperbilirubinemia has been the most common uncharacteristic 
physical finding during the earliest week of life. Over two third of neonates build 
up clinical jaundice. The physical finding like yellowish discolouration of the 
mucous membrane in newborn is due to accumulation of indirect bilirubin. 
Unconjugated hyperbilirubinemia is a normal physiological occurrence in most of 
the infants. Neonatal hyperbilirubinemia nearly influences 80%  preterm and also 
60% term neonates during initial week of life . 
Among term newborn 6.1% contain a serum bilirubin over 12.9 mg%. 
Serum bilirubin over 15 mg% is present in 3% of term newborns. Nevertheless 
untreated, severe unconjugated hyperbilirubinemia is potentially neurotoxic . 
Hyperbilirubinemia in neonate’s being a manifestation of undeveloped 
conduit of excretion of bilirubin by the  liver. It  is largely the frequent cause for 
newborns getting admitted again in primary days of living in current era of 
postnatal discharge from hospital. Neonatal hyperbilirubinemia is a cause of 
concern for the parents . Premature infants have neonatal jaundice at very elevated 
frequency of which necessitate curative interference when compared to term 
neonates.  
High values of unconjugated bilirubin could proceed towards bilirubin 
encephalopathy and later kernicterus through overwhelming permanant 
neurological development problems. Conjugated hyperbilirubinemia reflects 
impending systemic illnesses or severe hepatic disorders of the liver . Hence aptly  
managing neonatal hyperbilirubinemia is of supreme significance. 
 
 
Hyperbilirubinemia can be treated either by phototherapy or exchange transfusion 
or pharmacologic agents.  
Phototherapy plays a major function in prevention and management of  
hyperbilirubinemia. Phototherapy transforms bilirubin into isomers that are 
dissolvable in water which are  capable of being excreted devoid of conjugation 
that occur in the liver (Stokowski, 2006). 
Ultimate value of phototherapy relies on the kind of light source used (i.e. 
dosage, spectral release curve, deepness of infiltration), the space amidst the light 
and the infant, the surface area to be treated, the etiology of the jaundice and also 
value of total serum bilirubin at  phototherapy’s onset. 
The aims of phototherapy are to avoid the previously high total serum 
bilirubin level from increasing, to thwart the happening of encephalopathy or 
kernicterus and to stop the total serum bilirubin from getting higher to a level that 
needs exchange transfusion. 
The foremost exhibited phototherapy’s value has been diminishing the 
need for exchange transfusion. As any treatment has its side effects, phototherapy 
also has its adverse effects like hyperthermia, feed intolerance, loose stools, skin 
rashes, bronze baby syndrome, retinal changes, dehydration, hypocalcemia, 
redistribution of  blood flow and genotoxicity . 
Numerous investigations have been carried out to establish the security of 
phototherapy in the management of neonatal hyperbilirubinemia. Unlike other 
side effects, a few studies are currently available that depicts the adverse effects of 
 
 
phototherapy on serum electrolytes. Hypocalcemia is one of the known adverse 
effects. 
90% of preterm and 75% of fullterm neonates develop hypocalcemia after 
being subjected to phototherapy. Hypocalcemia can cause serious complication 
like irritability, jitteriness, convulsion and apnea. Phototherapy induced 
hypocalcemia is a significant problem. Hence emphasis is given in special 
reference to hypocalcemia. 
Therefore this study is aimed in determining the changes in serum 
electrolytes sodium, potassium, chloride and bicarbonate in addition to calcium in 
term babies receiving  phototherapy for jaundice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
 
1. To estimate the serum electrolytes in term neonates before and after 
phototherapy.  
2. To compare the occurrence of phototherapy induced electrolyte changes in 
term neonates before phototherapy and after phototherapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
HISTORICAL ASPECTS  
The record of bilirubin actually reverses several centuries, when neonates 
were found with jaundice. Towards the eighteenth century’s ending latest reports 
of jaundice in newborns appears to have started. One of the works was done 
through Jean Baptiste Thimotee Baumes (1806).  
He elaborates lethargy, poor intake, symptoms of cerebral association and a 
setback in passage of meconium would have been linked in the company of or 
itself reason of neonatal jaundice.                                                                                                                  
Association of newborn jaundice with absence of free discharge of 
meconium was stated by Condie (1853).                  
The first depiction of bilirubin related discoloration of the brain in a 
kernicteric neonate had been attributed by Johannes Orth (1875). He suggested 
the occurrence of yellowish and reddish tincture and substances in the appendages 
of neonates. 
Assessment of the brain with help of microscope by him, exposed to 
facilitate neurons within the basal ganglia were stained with yellowish colour 
while that of adjacent parts have not been stained. 
            The term “Kernicterus ” was  initially invented by Christian Schmorl in 
Dresden (1904). 
The yellowish tint of brain vanished later if not that tissue be safeguarded 
within formalin which was first  noted by Schmorl . 
 
 
In 1908 a case of icterus gravis neonatorum in families was published by 
Hermann J. Pfannenstiel. 
Cases in which single families had jaundice and kernicterus were published 
by Arkwright, J.A. (1910), Rolleston, H.D. (1910).              
The relationship among hyperbilirubinemia and brain injury in a newborn 
infant with erythroblastosis fetalis was made by Guthrie  L (1914) and was  
attributed as the first to issue an explanation of kernicterus.             
Diamond, et. al.,  in 1932, issued a key paper that explained the clinical 
setting of erythroblastosis fetalis (Blackfan, K., Baty, J., and Diamond, L1932) .   
A more rigorous type of neonatal jaundice accepted was Icterus gravis, 
often related with intense anaemia, atypical neurological conclusion  and demise.  
Several years later the grounds of icterus gravis equivalent to alloimmune 
hemolytic disorder would not have been acknowledged till the blood groups of 
human were studied.  
In 1940  danger of recurrence in families was established by the invention 
of the Rh group which were present as red cell antigens . 
When development took place in the methods for exchange transfusion in 
neonates the etiology of hemolytic disease which occurred in newborn was 
eventually illustrated. A book disorders of blood in case of children was in print in 
1944  Blackfan, et. al.,(Blackfan, K., Leister, C., and Diamond, L).     
The difficult method of exchange transfusion when needed was included 
and done by John Barrett,  MD, Edwin Forman, MD, Frank Giunta, MD, in 
1940s - 1960s . 
 
 
By1950, Vaughan, et. al., related erythroblastosis and kernicterus (Allen 
F., Diamond, L ., and Vaughan V). 
Unconjugated bilirubin crosses the placenta without difficulty and in the 
perceptive of how  fetal hyperbilirubinemia was absent and its levels tending to 
augment soon after birth was shown by Schenker (1963) (Dawber, N., Schmid, 
R., and Schenker, S., 1964). 
Simultaneous drop of birth rates in 1970s was associated with discovery of 
Rh – immune antiglobulin in 1968.  
Appearance of  red- blue pigment was found during 1883 when Ehrlich 
added diazo reagent with bilirubin in urine. 
            In 1918 Van den Bergh introduced diazo reaction. 
            Bilirubin glucuronide produced the direct moiety was stated by Schmid, 
et. al., in 1956 . (Billing, B., Lathe, G., Schmid, R., Talafant, E., and Cole, P.) 
             In 1959, Odell studied binding of bilirubin with the protein (1959). 
             In 1956 the foremost discovery of utilization of phototherapy happened 
by chance, at England in Rochford Hospital which was located in Essex. Clean 
air and sunshine in the lawn benefitted the infants was the belief of the sister in 
the ward (Incharge Nurse) of the preterm baby unit. 
              Subsequent to publications of Dr. Cremer’s in the Lancet during 1958 
paediatricians in the United Kingdom started to employ phototherapy . 
Lucey, et. al., published an additional very significant document in 1968 (Hewitt, 
J., Ferreiro, M., and Lucey, J., 1968). The most honest adherent of the uses of 
 
 
phototherapy was Dr. Lucey, with excellent humor called himself the “Prince of 
Light ” . 
Avoidance of hyperbilirubinemia and kernicterus in neonates by means of 
photo therapy were critically studied by Dr Lucey .  
Swift excretion of products of phototherapy which were photo-degradable 
were in bile and urine .This idea was put forth by Ostrow, J (Ostrow, J. 1967).      
  
 
 
BILIRUBIN METABOLISM 
1) SYNTHESIS OF BILIRUBIN: 
 The final product of metabolism of heme is bilirubin . Hemoglobin and  
various oxidative enzymes including  cytochromes present in the mitochondria and 
cytochromes of the microsomes (P-450) in the liver possess heme . So bilirubin 
present in the plasma is approximately 85 % erythropoietic and15% non-
erythropoietic. The two sources from which erythropoietic fraction originates are: 
normal aging erythrocytes in the circulation and the juvenile faulty red cells 
present in the bone marrow (Stevenson et al., 2001). 
As per the significance monocytic macrophages, reticulo-endothelium in 
each organ more particularly in the spleen, liver and bone marrow produce 
bilirubin from erythropoietic heme. The hepatocytes produce bilirubin from non-
erythropoietic  heme. An oxygenase breaks the tetrapyrrolic ring  present in heme . 
A tetrapyrrolic sequence devoid of iron is formed from the tetrapyrrolic molecule 
(Dennery et al., 2001). 
During the end of 1960s heme oxygenase was identified as  the enzyme 
very indispensable for bilirubin production. Heme of hemoglobin or proteins 
which contain  heme are degraded forming biliverdin, the green coloured pigment. 
Biliverdin reductase reduces biliverdin to unconjugated bilirubin, which is the 
orange-yellow coloured pigment. 
The alpha- bridge carbon that is oxidized is extruded as carbon monoxide 
and exhaled through the lungs . There is release of Iron in this course of action and 
preserved for reuse (Verman et al., 2004). 
 
 
2) BILIRUBIN TRANSPORT IN BLOOD 
           The reticulo endothelial cells set free bilirubin in the general circulation 
which    quickly gets attached to albumin. One gram of albumin can bind with 8.3 
mg of bilirubin at the primary binding site. However in the neonate, decreased 
albumin levels and presence of substances competing with bilirubin for the same 
binding sites can reduce the binding capacity e.g. long chain fatty acids from 
breast milk, sulphonamides and salicylate (Gourley, 2001). 
Only bilirubin which is not bound to albumin enters the brain by crossing 
an intact blood-brain barrier (Maisels, 2008). 
3) HEPATIC UPTAKE OF BILIRUBIN 
          Hepatocytes take up bilirubin  on their sinusoidal surface. There is breakage 
in the bond of albumin bilirubin . Albumin remains in the plasma. There is entry 
of  free molecule of bilirubin into the hepatocyte. There is very quick uptake. The 
impairment in taking up of bilirubin  by hepatocytes will result in unconjugated 
hyperbilirubinemia (Moersehel et al., 2008). 
4) HEPATIC INTRACELLULAR BILIRUBIN TRANSPORT: 
           Within the hepatocyte cytoplasmic proteins: ligandins and Z protein are 
found attached with  bilirubin . 2% of cytosolic proteins are constituted by 
collection of enzymes  called Ligandins . Fatty acids are seen bound with Z 
protein . The avoidance of reflux of free bilirubin from hepatocytes into the 
circulation is the primary function of the Z proteins (Hansen, 2009). 
 
 
 
 
5) CONJUGATION WITH GLUCURONIC ACID: 
           Glucose is normally present in hepatocytes. UDP-glucose dehydrogenase 
act on glucose to form Glucuronic acid (Huang et al., 2002). Unconjugated 
(indirect) bilirubin is converted to water soluble conjugated (direct) bilirubin in 
the smooth endoplasmic reticulum by uridine diphosphate glucuronyl transferase 
(UDPGT) enzyme. This enzyme catalyzes the formation of bilirubin 
monoglucuronide which may be further conjugated to bilirubin diglucuronide. 
Both mono and diglucuronide forms can be excreted into the bile canaliculi 
against the concentration gradient. 
Inherited deficiencies of the conjugating enzyme uridine diphosphate 
glucuronyl transferase (UDPGT) can cause severe hyperbilirubinemia in neonates 
(Criggler Najjar syndrome) (Huang et al., 2002). 
By augmenting the action of bilirubin transferase bilirubin conjugation and 
excretion is favoured on administration of substances that induce  microsomal 
enzyme  such as phenobarbital, glutethimide and antipyrine (Wong et al., 2007). 
In summary: Glucose on combining with UDP-Glucose-dehydrogenase;  UDP 
glucuronic acid is formed. 
UDPGA combines with  bilirubin and Glucuronyl transferaseto form 
bilirubin mono & di- glucuronides. 
6) SECRETION OF BILE BY HEPATOCYTES: 
            The liver has an endocrine part and an exocrine part. Products such as 
blood proteins and coagulation factors produced by the liver are secreted 
internally into the blood through the sinusoidal surface (Thaler M 1996). The bile 
 
 
and several other substances such as the final products of detoxification are 
secreted externally into the biliary tract (Wong et al., 2007). 
7) INTEST1NAL METABOLISM OF BILIRUB1N:  
According to the following sequence urobilin is formed in the intestine 
when bilirubin gets reduced to:  
 Bilirubin glucuronide combines with bacterial enzymes or intestinal beta 
glucuronidase  to form  free bilirubin 
Free bilirubin is acted upon by bacterial dehydrogenase to form urobiliogen 
(colourless) 
Urobilinogen is in turn acted upon by dehydrogenase and UROBILIN 
(orange-yellow in colour) is formed. 
              It is through the faeces excretion of the vast quantity of bilirubin, 
stercobilinogen, stercobilin, urobilinogen and urobilin takes place. Reabsorption 
of little quantities of bilirubin along with urobilinogen are done through the 
intestine and it reaches the liver. Reconjugation of  bilirubin occurs  within the 
liver and is excreted through the faeces. In the urine there is excretion of 
urobilinogen which was reabsorbed (Moershel et al., 2008). 
8) BILIRUBIN EXCRETION: 
Just when the level of conjugated bilirubin in the plasma is greater than  the 
normal it is excreted through the urine. Normal subjects do not contain conjugated 
bilirubin in  urine . In conditions of unconjugated hyperbilirubinemia,  as it 
happens in cases of hemolysis  conjugated bilirubin is not excreted through the 
urine (Dennery et al., 2001). 
 
 
                                    NEONATAL HYPERBILIRUBINEMIA 
 Neonatal icterus or jaundice in Neonates otherwise hyperbilirubinemia 
in Neonatal period (accepted in Greek the same meaning as ἴκτερος), 
adjective is: icteric, which appeares as yellowish discolouration occurring 
in mucous membrane of a neonate due to elevated serum bilirubin 
concentration. 
 A commonly faced difficulty,  neonatal hyperbilirubinemia by  definition is 
rise levels of total serum bilirubin more than 5 mg in one dL or 86 μmol in 
one Litre.( Slusher et al., 2004) 
 Tetrapyrrole prosthetic group present in haemoglobin and  cytochromes 
gives rise to biliburin . 
 
 Application of pressure by a finger blanches the skin which detect jaundice 
in newborn by showing the details of the underlying skin and subcutaneous 
tissue. 
 With skin nature and body area the serum bilirubin level necessary to effect 
jaundice changes. 
 
 
 When serum bilirubin reaches a value at two to three mg in one dL or 34 to 
51μmol in one litre ; jaundice generally happen to be evident in sclera and 
in value between 4 and 5 mg in one dL or 68 to 86 μmol in one litre 
jaundice  becomes happens to be in face  .    
 
 Normal values of serum bilirubin (Stoll and Piazza, 2007). 
    Age  Preterm Full term 
Cord blood 2mg/dl 2mg/dl 
0-1 Day 8mg/dl 6mg/dl 
0-2 Day l2mg/dl 8mg/dl 
2-5 Day 16 mg/dl 12 mg/dl 
 
 Jaundice look as if to proceed in a course starting from head and ending in 
foot, as bilirubin levels rises. When the level increases to 15 mg/dL 
(258 μmol/L) it becomes apparent upto the level of umbilicus and when the 
level increases to 20 mg/dL (340 μmol/L) it becomes apparent upto the 
feet. In the first week of living slightly additional than 50% of all neonates 
become apparently jaundiced.                  
 Based on its reason and the degree of increase hyperbilirubinemia may be 
safe or dangerous . No matter what may be the bilirubin level few reasons 
of  jaundice are very hazardous . 
 Once the level is elevated enough  hyperbilirubinemia of any cause is a  
concern. Based on age , level of prematurity and  health position the verge 
 
 
for concern changes.  The threshold is taken to be a level > 18 mg/dL 
(> 308 μmol/L) in term infants. 
 All neonates have some hyperbilirubinemia and most have benign 
outcomes when monitored and treated, if necessary, in a timely manner. 
Neonatal jaundice may be recognized in about 60% of infants born at full-
term during first week subsequent to being born (Bhutani along with 
Johnson, 2009). 
 
Incidence of Neonatal Hyperbilirubinemia       
  In the first week of life nearly every newborn has an unconjugated serum 
bilirubin level above 30μmol/L (1.8 mg/dL) making neonatal hyperbilirubinemia 
very common (Schwoebel et al ., 2004). Visual detection of jaundice by health 
care providers, which differs extensively. It relies both on notice of the observer 
and on features of the infant like race and maturity. Infants to be tested are thus 
recognised. There is elevated incidence in East Asian, American Indians and 
lesser in blacks. Incidence rate is higher Greeks who are residing in Greece than 
Greek ancestry existing exterior to Greece (Ipek and Bozakut, 2008). People 
existing at higher altitudes have greater incidence (Hansen, 2009). 
                Phototherapy was suggested by the American Academy of Paediatrics 
for 4.3% of the total 47,801 infants who had total serum bilirubin levels in the 
recommended range. It was shown  in a 2003 study in the United States(Atkinson 
et al.,2003).10.5% of infants born in term and  25.3% of infants who were born 
near-term had significant jaundice was the report of a study done in Turkey 
 
 
(Sarici et al., 2004).In Egypt about 20.4% of newborns develop jaundice yearly. 
Incidence of jaundice was found to be higher in low birth weight infants (35.6%) 
compared to normal birth weight infants (16.9%) (Mansour et al., 2005). 
Therapeutic interference is necessary for premature babies who have much 
greater occurrence of neonatal jaundice when compared to term neonates (Porter 
and Denim BL 2002). Most frequent morbidity seems to be hyperbilirubinemia 
among 65% of 137 very low birth weight neonates who were born in a period of 7 
years in AIIMS. 
 NEONATAL HYPERBILIRUBINEMIA CLASSIFICATION: 
A) Classification depending on conjugation of bilirubin 
B) Classification based on the onset of jaundice 
   A) Classification based on conjugation of bilirubin 
o Unconjugated (Indirect hyperbilirubinemia) 
o Conjugated (Direct hyperbilirubinemia) 
    B) Classification based on the onset of jaundice 
1. Jaundice appears within first 24 hours 
2. Jaundice appears on daytime two otherwise three 
3. Jaundice appears after first week 
4. Persistent jaundice during the first month 
I) Unconjugated (Indirect hyperbilirubinemia) is further classified into 
a. Physiological  jaundice 
b. Hemolytic causes –  intrinsic, extrinsic  
c. Non-hemolytic causes 
 
 
d. Substances / disorders affecting binding of bilirubin to albumin 
a) Physiological  jaundice During their first week many infants build up visible 
jaundice due to rise of unconjugated bilirubin level.  
This frequent condition is known as physiological jaundice. 
o Mostly in the initial 24 hours it is not present  
o Occasionaly rises above 5mg/dl in a day 
o Fraction of direct bilirubin is mostlly less than 2 mg/dl. 
1. Infants born at term : 
 in the initial first week of living 50-60% of neonates are jaundiced  
 at 3–5 days level of total serum bilirubin reaches highest range  
 serum bilirubin does not exceed 13 mg/dl  
 it usually disappears by 14 days 
2. Infants born at Preterm: 
 elevated occurence of noticeable jaundice is more than in term 
infants. 
 total serum bilirubin reaches highest range at age of 5-7days.  
 serum bilirubin does not exceed 15 mg/dl  
 It usually disappears by 21 days 
           Investigation should be carried out in neonates who fail to fulfil the above 
criteria and managed as pathological jaundice (Johnson and Terry, 2006). 
Etiology of physiological jaundice 
 Physiological jaundice is caused by: Usually unconjugated bilirubin is 
converted to conjugated bilirubin and gets eliminated into the gastrointestinal 
 
 
tract. This converting action which is carried out by glucuronyl transferase is 
decreased. 
 In the fetus before birth, the enzyme has been keenly kept at low levels, as 
bilirubin should continue to stay unconjugated so as to pass through the 
placenta and in view of preventing  accumulation.  
 Enzyme glucuronyl transferase takes a few days, after birth to regains its 
function. 
 In adults life span of red blood cells 100 to 120 days whereas it is shorter, 
being just ranging between eighty and ninety days in a infant born at term. 
 Increase in absorption of bilirubin back again into the circulation due to 
little conversion by the intestinal flora of bilirubin to urobilinogen . 
In newborns those who are breastfed two types of jaundice occur. Mostly 
oboth the types are not dangerous.  
They are             
i. Early - Onset Breastfeeding jaundice    
ii. Late - Onset Breast milk jaundice  
Breastfeeding Jaundice  - Early Onset 
 Sizable energy deficit in the former a small number of days in life makes 
the  neonates who are breast-fed to be  prone to bigger jeopardy for early-
onset inflated physiologic jaundice  
 Delay in passage of meconium and mild dehydration occur due to low 
volume and number of feedings.  
 
 
 Moderately jaundiced (value of total serum bilirubin beyond 12 mg per dL) 
or severely jaundiced (value of total serum bilirubin exceeding 15 mg per 
dL) occurs in breastfed infants three to six times than formula-fed 
newborns (Eneh AU, Uguv 2009). 
  Few newborns those having  reduced milk ingestion plus those in whom  
containing dehydration or decrease in energy ingestion have elevated 
enterohepatic circulation of bilirubin. Decreased level of intestinal bacteria 
which converts bilirubin to nonreabsorbed substances could cause the rise 
in enterohepatic circulation ( John P Cloherty). 
 
Late-Onset Breast milk jaundice  
Breast milk jaundice varies from breastfeeding jaundice. It occurs in 
otherwise healthy, full term, breastfed babies. It is characterised by indirect 
hyperbilirubinemia  in breast fed newborn. It occurs between five and seven days 
of life furthermore reaches peak by second week. It persists longer than 
physiological jaundice. It is caused by the following reasons:  
 
1. At the time of birth, the gut is free from infective organisms and there is 
delay establishment of normal gut flora. Conjugated bilirubin is 
converted to stercobilinogen by the bacteria in the adult gut and 
excreted in the stool.  
 
 
2. When there is lack of adequate bacteria, brush border β-glucuronidase 
de-conjugate bilirubin which is then reabsorbed. This route of 
reabsorption is known as enterohepatic circulation.  
3. Augmented levels of substance called epidermal growth factor present 
in milk of mother causes increased uptake of  bilirubin in the intestine 
(enterohepatic circulation)  in babies who are breast fed.  
4. Bilirubin deconjugation and enterohepatic recirculation are amplified 
by glucuronidase present in breast milk (Gartner and Hershel 2001). 
5. 3-alpha-20-beta pregnanediol which is a metabolic product of 
progesterone is present in breast-milk of certain women. Activity of 
uridine diphosphoglucuronic acid glucuronyl transferase predisposed in 
favor of conjugation and successive elimination of bilirubin is inhibited 
by pregnanediol.  
6. Conjugation of bilirubin is decreased in the infant’s liver, since the 
action of glucuronyl transferase is just 0.1-1 percent of the level of 
grown person. Elevated values of bilirubin in blood occur due to 
inhibition of conjugation of  bilirubin.  
7. Hepatic glucuronyl transferase is inhibited by lipoprotein lipase, an 
enzyme that is present in breast milk resulting in decrease in 
conjugation and ensuing excretion of bilirubin. 
 
During month of July in 2004, the American Academy of Peadiatrics 
made in print protocols which would decrease beginning of avoidable 
 
 
circumstances. As per AAP Subcommittee on Hyperbilirubinemia, for each 
baby born by 35 weeks or additional weeks of pregnancy, successful 
breastfeeding ought to be promoted: 
Recommendation 1: Clinicians should give advice mothers to feed their 
newborn babies atleast 8 to 10 times per day for first numerous days. 
Recommendation 1.1: The AAP suggests in opposition to regular     
supplementation  of non dehydrated infants who are breastfed with water 
or (sugar) dextrose water. 
b) Hemolytic causes: 
   Intrinsic 
RBC enzyme defects  
o Pyruvate kinase deficiency 
o Glucose-6-phosphate dehydrogenase deficiency (Siberry and 
Iannone 2000) 
RBC membrane defects  
o Hereditary elliptocytosis 
o Hereditary spherocytosis 
Globin synthesis defect 
o Thalassemia 
o sickle cell anaemia 
Systemic conditions  
o Arteriovenous malformation 
o Sepsis 
 
 
Extrinsic  
o Kell incompatibility 
o ABO incompatibility (Haque and Rahman 2000) 
o Alloimmunity (The blood from cord or neonate that gives direct 
Coomb’s  test positive and maternal blood which gives indirect 
Coomb’s test positive) 
o Rhc incompatibility  
o Other mismatches in blood group leading to illness of the newborn with 
hemolysis. 
o Rh incompatibility 
c) Non-hemolytic etiologies 
i) Decreased hepatic uptake and conjugation of bilirubin 
 Breast milk Jaundice (pregnanediol inhibits glucuronyl transferase )     
 Infants of Diabetic Mothers  
 Pyloric stenosis  
 Criggler Najjar Syndrome  
 Hypothyroidism 
 Gilbert Syndrome  
 Immaturity of  glucuronyl transferase action in all newborns 
ii) Increased enterohepatic reabsorption 
 Bowel obstruction  
 No enteric feedings  
 Breast feeding jaundice (due to dehydration from inadequate milk supply) 
 
 
d) Substances / disorders affecting binding of bilirubin to albumin 
 Fatty acids in nutritional products 
 Asphyxia 
 Acidosis 
 Hypothermia 
 Hypoglycemia 
 B) Conjugated (Direct Hyperbilirubinemia) 
Whichever of the subsequent aspects illustrates pathological jaundice: 
a) Direct bilirubin above 34 μmol/l (2.0 mg/dL). 
b) Clinical jaundice which appears within initial twenty four hours . 
c) Augmentation in the value of total bilirubin above 8.5 μmol/l (0.5 mg/dL) 
per hour or (85 μmol/l) 5mg/dL per 24 hours. 
d) Total bilirubin above331.5 μmol/l (19.5mg/dL). 
II)Classification based on the onset of jaundice 
1)Jaundice appears within first 24 hours: 
 Pathological jaundice 
 Erythroblastosis fetalis. 
 Intrauterine infection (TORCH)  
 Sepsis 
 Extravascular hematoma 
 
 
 
 
 
2)Jaundice appears on the second or third day: 
 Physiological jaundice 
 Criggler-Najjar syndrome 
 Early onset breast feeding jaundice 
3)Jaundice appears after first week: 
 Breast milk jaundice 
 Extra hepatic biliary atresia 
•   Hypothyroidism 
•   G6PD deficiency (Shahiary 1997) 
•   Galactosemia 
4) Persistant jaundice during the first month: 
•    Inspissated bile syndrome 
•    Hyperalimentation 
•   Congenital infection (Stoll and Kligeman, 2004)           
Elevated bilirubin formation and reduction in bilirubin conjugation play a 
significant part in the pathogenesis of newborn jaundice (Ogunlensi TA 2007). 
There are several risk factors which influence the severity and period of 
hyperbilirubinemia though physiological jaundice is present in many newborns,.  
        When thee are mutations in the gene coding UDP-glucuronosyl transferase 
1A1 (UGT1A1) present with other risk factors  the incidence and rigorousness of 
neonatal jaundice have been elevated (Muslu et al,2007). 
 
 
 
 
         Risk Factors for Hyperbilirubinemia (Dennery et al., 2001) 
Maternal Factors  Neonatal Factors  
1. Drugs: Vitamin K 3, diazepam ,   
    oxytocin  
2.Inadequate breast feeding 
3. Blood type whether Rh or ABO 
    incompatibility  
4. Maternal illness  
(Oladakun A et al., 2009) 
5. Ethinicity- Asian, Native     
    American  
1. Infections: TORCH or sepsis  
    (TORCH- cytomegalovirus , herpes 
simplex viruses,  rubella,   toxoplasmosis). 
2. Birth trauma: instrumental  delivery, 
cephalohematoma,  cutaneous bruising  
3. Infrequent feedings 
4. Drugs: erythromycin,  chloramphenicol  
5. Excessive loss of weight after birth  
6. Polycythemia. 
7. Delayed meconium passage 
 8. H/o Prematurity  
9. H/o Previous sibling with  
      Hyperbilirubinemia. 
10. Being male in gender. 
 
  
 
 
Bilirubin Toxicity 
The most important effect of neonatal hyperbilirubinemia is  Kernicterus.  
Acute or chronic hyperbilirubinemia giving rise to deposition of 
unconjugated bilirubin  in basal ganglia and brain stem nuclei and producing brain 
damage is kernicterus (Soorani- Lusing I et al., 2001). Kernicterus occurs even 
till date and can be prevented nearly forever though it is unusual now. (Steven 
and Shapiro 2003). 
More care must be taken supposing if bilirubin’s value is more than 25 mg 
per dL (428 μ mol per L)though the jeopardy of bilirubin toxicity is almost 
unimportant in case of healthy term newborn who is exclusive of hemolysis and 
 in the term newborn who is by way of hemolysis, a bilirubin level more than 20 
mg per dL (342 μ mol per L) is a stress. 
Inside the intravascular space bilirubin attached to serum albumin  is 
present usually. If injury has happened due to asphyxia, sepsis, hyperosmolality, 
hypoperfusion, hypoxia or acidosis in the neonate bilirubin crosses  the blood-
brain barrierand produces kernicterus ( Amin SB 2004). 
The consequences of bilirubin excess has been unalterable in addition 
frequently overwhelming (Chang et al ., 2009). Three to four days later after birth 
earlier signs of kernicterus which are delicate and imprecise, classically appear. 
At whatever time all through the neonatal period hyperbilirubinemia may cause 
kernicterus. 
The newborn who is affected starts to show delayed effects of bilirubin 
toxicity after the initial week of life (Seoud et al., 2007). Mildly mental 
 
 
retardation delays in developmental and motor function, sensorineural hearing 
loss and are features of chronic bilirubin encephalopathy (apparent by three years) 
produced if the infant is able to survive after the primary severe neurologic 
damage (Newman , T. B., et al. 1990). 
High rational advance to plans used for the analysis of jaundice in the 
newborn is achieved if an alertness of the risk factors and their possible role to 
serum bilirubin levels is created (Maisles, 2006). 
 
Investigation of jaundice 
a) Estimation of bilirubinThe diagnosis of jaundice and its severity is 
substantiated by measuring the level   of bilirubin . A sample of blood or by 
means of a sensor  placed over the skin the level can be calculated .  
i) Clinical Assessment In light  of natural source an inspection visually is  carried 
out. 
 While the  bilirubin level increases, from head to toe the depth of jaundice 
progresses. Level of serum bilirubin (SBR) along with the intensity of skin  
discolouration are described by ruleof Kramer  
 
 
Region Lower 
body, 
 thighs 
Neck 
and Head 
Hands,  
feet 
Chest Arms,legs 
below 
knees 
SBR in mol/L 200 100 >250 150 250 
 
 
Inspecting the infant visually and rule of Kramer,  just can be used to 
assess the intensity of jaundice. 
Serum bilirubin assessment should not be done by clinical evaluation of the 
depth of jaundice as the error a inter-observer is wide. In the infants having 
pigmented skin the estimation is mostly undependable. 
ii) Transcutaneous hand held bilirubinometer:  
 This is a transportable, rechargeable and also hand held but expensive 
and    more refined.  
 a xenon tube gives rise to a strobe light and that light goes all the way 
through the subcutaneous tissue when we apply pressure over the 
photoprobe,.  
 By travelling in the second fiber optic bundle to reach the 
spectrophotometric module the light which gets reflected is  returned 
(Ebbesen A 1996). 
 After correction is done for hemoglobin the strength of the yellow colour 
in this light, is calibrated and immediately displayed in arbitrary units. 
 To guarantee that total bilirubin levels are securely less than those requiring 
interference this portable bilirubinometry is sufficient for infants with mild 
jaundice. 
 For individualising babies who need sampling capillary blood or phlebotomy to 
measure serum  bilirubin  transcutaneous bilirubinometry may be valuable  in 
the infants with moderate jaundice.   
 
 
 To select infants to speedy and forceful therapy this hand held bilirubinometry 
may be a helpful device in infants with extreme jaundice, ( Rubaltelli FF et al., 
2001). 
  iii) Total serum bilirubin level : 
 For a neonate having jaundice moderately and comes on the third or second day 
of living devoid of  physical examination results and history indicative of  
pathologic progression generally measuring the level total serum bilirubin  test 
alone is needed . 
 Earlier assessment of fractions of bilirubin is required for infants in whom 
jaundice persists after the initial 7-10 days of life and in those with 
thrombocytopenia hepatosplenomegaly, or other findings suggestive of 
hepatobiliary disease,  petechiae,  congenital infection or metabolic disorder . 
Additional investigations along with bilirubin may be needed in the situations 
given below : 
 jaundice presented by infants later than third or on the first day of life 
 some infants when being born being anemic  
 otherwise sick appearing infants 
 increase in levels of serum bilirubin in some infants necessary to start 
management 
 persistence in some infants with considerable jaundice further than the 
primary 2 weeks of life  
 pregnancy, family, maternal or the case histories showing the likelihood of 
a pathologic event in certain infants.  
 
 
 physical assessment exhibiting features which are not clarified by 
uncomplicated physiologic hyperbilirubinemia in some of the infants. 
The other investigations include: 
b) Values of hemoglobin and hematocrit   
c) Determination in infant and mother of Rh and blood type. 
d) Levels of albumin in serum  : 
 Since at the initial high-attraction binding site albumin couples bilirubin at 
a ratio of 1:1 this measurement looks to be a useful accessory in finding the 
risk of toxicity strength. 
e) In the infant direct antiglobulin test (DAT)which is direct Coombs test. 
f) In breath measuring carbon monoxide end-tidally:  
 a manifestation of production of bilirubin is end-tidal carbon monoxide in 
breath (ETCO)  
 Persons with hike in production of bilirubin and so at an augmented danger 
of mounting more levels of bilirubin can be noticed by measuring ETCO. 
  ETCO is easily measured by an apparatus which has been recently 
developed. 
g) Hour-specific bilirubin values depicted by nomogram : (Bhutani VK et al, 
2001) 
 Infants who are prone to acquire rise in values of serum bilirubin whether 
before or during the time of discharge from hospital can be judged by this 
helpful tool.  
 
 
 Keen follow-up monitoring along with frequent measuring of  bilirubin is 
needed for infants recognized by this manner.  
 For both values of bilirubin assessed in the serum and for transcutaneously 
measured values the ability of prediction has been revealed.  
 Beyond that previously got by plotting bilirubin value each  hour against 
the  nomogram; result of  positive DAT (Direct antiglobulin test) test did 
not adjoin at all importance for clinically managing of those babies. 
  In infants having ABO incompatibility who are DAT (Direct antiglobulin 
test) - positive  nomogram appears to function well 
 h) Levels of conjugated bilirubin:  
                  In the situations which were described before measuring bilirubin 
fractions may be needed. Only if frequent measurements assure the occurrence of 
an high conjugated bilirubin  ; measuring direct bilirubin are usually incorrect and 
are liable to considerable disparity in inter laboratory as well as intra laboratory . 
So in general it is not a responsive tool in the diagnosis of cholestasis .  
 i) Erythrocyte morphology identification by peripheral blood film  
J)  Performing reticulocyte count 
 k) Viral and/or parasitic infection identification :  
For infants with thrombocytopenia or other evidence of  hepatocellular 
disease,  petechiae,  hepatosplenomegaly these tests may be needed.    
l) Examining urine for reducing substance :  
If the infant has taken adequate quantities of milk this test is a helpful for 
screening  galactosemia . 
 
 
m) Tests to assess liver function:  
In hepatocellular disease levels of alanine aminotransferase in addition 
toAspartate aminotransferase  are raised. In cholestatic disease levels of gamma-
glutamyl transferase along with Alkaline phosphatase  are often augmented.  
Biliary obstruction is established by A gamma-glutamyl transferase/alanine 
aminotransferase ratio above 1. But intrahepatic and   extrahepatic cholestasis 
cannot be distinguished ( Haber BA, Lake AM, 1990). 
n) Tests to assess thyroid function  
o) Measuring  blood gas:  
In acidosis, predominantly respiratory acidosis the threat of bilirubin CNS 
toxicity is augmented. 
  p) Bilirubin-binding tests: 
Unbound bilirubin is among one of numerous factors by which that  
toxicity of  bilirubin can be mediated /modulated even though high levels of 
unbound ("free") bilirubin are linked with an very high danger of bilirubin 
encephalopathy,  
 Treatment 
A practical consideration which deals through the treatment in the healthy 
newborn born at term’s hyperbilirubinemia was formed during 1994 October by 
the Subcommittee on Hyperbilirubinemia and Provisional Committee for 
Quality Improvement of the American Academy of  Pediatrics (AAP). 
 
 
 
 
In three means neonatal hyperbilirubinemia can be managed: 
a. Mechanical removal of bilirubin by exchange transfusion (Forfar JO 
1958). 
b. Convertion of bilirubin into substances which can bypass the liver's system 
of conjugation and their excretion either through the bile or through the 
urine devoid of metabolism by phototherapy (Cremer RJ  1958). 
c. Hastening the usual metabolic pathways for clearance of  bilirubin or 
inhibition of enterohepatic circulation for bilirubin by meddling with heme 
degradation and synthesis of bilirubin through the action of pharmacologic 
substances (YaffeSJ, Dorn LD 1990). 
A level of total serum bilirubin above which management of baby is needed is 
the definition of significant neonatal jaundice . 
  Phototherapy to be given to term neonates according to age in hours and also 
level of serum bilirubin (AAP, 1994; Cashore, 2000). 
(level of serum bilirubin) 
Hours of age          considering the phototherapy     requiring the phototherapy              
__________________________________________________________________ 
twenty four                              -                                                    - 
-twevty five hours 
 seventy two hours              >15 mg/dl                                 >18 mg/dl 
forty eight                           >12 mg/dl                                 >15 mg/dl 
 -forty nine hours 
more than  
seventy two hours               >17 mg/dl                                 >20 mg/dl 
__________________________________________________________________ 
Having relied upon the age and health condition of the neonate levels of 
bilirubin for beginning phototherapy differs (Weinberg 1992). Phototherapy must 
be given to newborn having  total serum bilirubin in excess of 12 mg/dL  . 
 
 
Phototherapy 
Isomerisation in which trans-bilirubin changes into water-soluble cis 
isomer of bilirubin is the mechanism through phototherapy exerts its action. Since 
blue light is more successful in the bilirubin break down it is normally used during 
phototherapy (Amato, Inaebnit, 1991).  
Exposure to blue light or concentrated green phototherapy was given to 
two separate groups of neonates having jaundice who were matched. The amount 
of decrease of serum bilirubin was calculated and it reflects the effectiveness of 
the treatment.  
Blue coloured lamps give a much quick  response when compared to the 
green lamps. Among the babies who were exposed to the green lamps recovery 
time from phototherapy was lesser. Since to see striking outcome exposure time 
must be more in green light it  is not generally in use (Dahi Far H). 
The danger of skin moles amidst children is more for treatment with 
ultraviolet illumination. But which has been used in phototherapy for taking care 
of neonate’s jaundice does not increase the threat of skin malignancy.  
Movement of bilirubin in the course of  metabolic system  of neonate is 
aided by augmenting feedings (Gartner L M 2001). By using overhead lamps the 
light may be functioned, in this method the eyes of the baby should  be covered . 
The light may be operated by using a device which is known as Biliblanket, that 
should be applied over the skin of the baby and below the clothes (Schuman AJ 
1992). 
 
 
Infiltration of tissue by means of light rises strikingly as wavelength is 
escalating . So  absorption of  light by bilirubin occurs powerfully close to 460 nm 
which is occupied by blue area of the colour scale. Under the subsequent 
conditions 'Biliblankets' plays some task : 
 To continue staying in the company of mother in postnatal ward and  permit 
infant to be in an open bed. 
 To make available treatment on the way of the part of body which has not 
been in front of the phototherapy unit being placed above head in the infants 
who are getting intensive phototherapy. 
 Treating as outpatient. (Costello SA, Nyikal I, Yu VY, et al 1995). 
The strength and wavelengths of the light in usage determines the quantity 
in which bilirubin photoproducts are developed. Phototherapeutic outcome is 
achieved by wavelengths that infiltrate tissue and that bilirubin absorbs  (Meberg 
1997). 
Considering these influences the most effective source for treating 
hyperbilirubinemia are most likely lamps that has output chiefly in the range of 
460-to-490-nmwhich is occupied by blue area of the colour band. 
The powerful output of the light source determines the effectiveness of 
phototherapy (Tan KL 1991). It is expressed as watts per square centimetre per 
nanometer (μW/cm2/ nm) covering a given band of wavelength after being 
measured by a radiometer or spectroradiometer.  
Either standard daylight or conventional phototherapy units have to convey 
a spectral irradiance of eight to ten μW per square centimeter per nanometer in the 
 
 
four hundred thirty to four hundred  ninety nanometre band, when placed twenty 
cm on top of the infant, thirty to forty μW per square centimeter per nanometer is 
delivered by unique blue fluorescent lamps . 
Conveying  a spectral irradiance of at a rate of thirty μW /cm2/ nm in the 
same bandwidth to the entire baby’s body surface area as much as possible is the 
definition of intensive phototherapy in accordance with the American Academy 
of Pediatrics. 
In phototherapyblue fluorescent tubes are extensively used (Seidman DS 2000). 
Normal blue fluorescent lights are possibly corresponding with typical white 
daytime lamps.Narrow-spectrum blue colour lamps which is special blue emerge 
to work most excellent (Ennver IF 1990). 
Fixed with the overhead heat origin of few radiant warmers, quartz lamps 
are also being used in one or two banks having three – four bulbs. The energy 
output is practically high when compared to spotlights also the energy field 
conveyed by them is to a great extent is uniform.  
The capacity to enhance energy delivery by moving lights near the neonate 
is restricted since the lamps are attached with the overhead heater component. 
In phototherapy units fiberoptic lights too are made use of. (De Luca G et 
al 1991). Elevated energy levels are conveyed by these units, capacity of the 
smaller "pads" are reduced when compared with bigger wrap-around blanket since 
spectral power (when we multiply irradiance with the extent of the irradiated 
region) is related to the extent of the field that is lighted (Karush G 1992). 
 
 
Loud sound from the fan of the light source along with a diminishion of 
energy delivered due to ageing and/or rupture of the optic fibers are the 
disadvantages in fiberoptic phototherapy units. Photodiodes are used as light 
source in some  fiberoptic units (Mills JF, Tudehope D 2001).  
The following are the advantages in fiberoptic phototherapy: 
 home phototherapy easily arranged  
 after joining along conventional overhead phototherapy units (double/triple 
phototherapy) there is likelihood for irradiating a huge surface area  
 overheating the newborn is reduced 
 eye shields not required 
 making the infant lie in a bassinet adjacent to the mother's cot phototherapy 
is  delivered                
In many recent phototherapy units light-emitting diode (LED) lights are 
instituted. (Kumar P et al 2010). Little power expenditure, reduced heat 
production and a  good deal prolonged duration of the light-emitting units (20,000 
hours) when compared with previous light sources are the advantages . 
The absorption range of bilirubin is being overlapped by blue LED lights that 
have a constricted spectral band of elevated-intensity light. The Cochrane 
Collaboration along with Tridente and DeLuca 2012had recently done review 
in procedures in which LED phototherapy is compared with other light sources. 
The effectiveness of LED lights in decreasing total serum bilirubin levels is in 
comparison with conventional light sources like fluorescent or halogen lamps is 
 
 
the conclusion of those authors of reviews. It is among LEDs in addition to blue 
fluorescent lamps development of bilirubin photoisomers can be  compared. 
Special blue fluorescent lamps or light-emitting diode (LED)  lights which 
is established to be valuable for phototherapy is currently advocated by American 
Academy of Pediatrics. Fiber-optic devices within which there is built-in filtered 
halogen lights too are in usage. 
           To treat infants with very elevated values of serum bilirubin "double" and 
"triple" phototherapy, which means the simultaneous usage of two or three 
phototherapy units in same patient is used 
The neonate’s space from the light and the region of skin exposed also 
influence the phototherapy’s dose and efficacy. So it is advisable to place the light 
source underneath the infant. Efficacy of phototherapy can be improved by 
placing aluminum foil or white cloth on both sides of the infant so that the light 
gets reflected.                  
Lowering the levels of bilirubin by increasing its elimination is the 
objective of phototherapy and it is effectively done by  phototherapy. As a method 
to cure jaundice in neonates sunbathing is not suggested nowadays (Maisels and 
McDonagh, 2006). 
The neonate’s eyes have to be constantly secured by opaque eye patches as 
the light can be harmful to the immature retina (Fok TF, Wong W, Cheung KL. 
1997). When the total serum bilirubin reduces less than the level at which 
phototherapy was started phototherapy can be safely terminated in infants who 
were treated (Meharban Singh 2004). 
 
 
Augmenting energy delivery and the accessible surface area are the 
important facts in the practical implementation of phototherapy. Following points 
should also be considered: 
 To decrease the risk of overheating and if homeostasis of temperature is 
observed carefully the distance between the baby and the device can be 
reduced down to ten-twenty cm . For quartz lamps this cannot be applied. 
 The inside of the bassinet should be covered with a reflecting substance, 
white cloth functions good in this condition. A white curtain can be hanged 
enclosing the bassinet and the phototherapy unit . Energy delivery can 
improve to several folds by these simple methods. 
   Apart from diapers the eyes which has to exist enveloped to lessen 
possibility of  injury to retina and the newborn ought to be left naked.  
 The distance from light’s origin and the infant's skin should be checked. 
The distance should not be more than fifty cm or twenty inches when using 
fluorescent lamps. 
 View concerning efficacy of phototherapy have to be customized to the 
circumstances. A considerable diminution of the rate of rise may be 
acceptable for infants in whose serum bilirubin concentrations continue to 
increase. 
 Phototherapy should effect in quantifiable reductions in levels of serum 
bilirubin within some hours for babies whose concentrations of  serum 
bilirubin are nearer to their maximum value. 
 
 
 The preliminary rate of decrease will be the more striking in infants who 
had the elevated serum bilirubin concentration in the beginning. 
 As photoenergy decline near the circle's border make sure that the infant is 
positioned at the middle of the light’s circle when spotlights are being 
used. 
 Monitor the infant very much closely to make certain the baby does not 
shift away as of  high-energy region.  
 In small premature infants spotlights are possibly more suitable when 
compared to larger near-term infants. 
 Urine specific gravity, weight loss and output of urine, and should be 
monitored in the infant. Adjustments are made fluid intake consequently.  
 Since milk acts like a means of transport for bilirubin away from the gut 
milk is the ideal fluid particularly for infants those who are fed orally  
( Coglayan, S., et al.1993) . 
 Supervising should be done each hour or each other hour for infants who 
get admitted with severe serum bilirubin values above thirty mg/dL. 
Individualization is needed for timing the follow-up testing of serum 
bilirubin (Kishan 1998). 
 Observing for each 6-12 hours is most likely sufficient in infants having 
much moderate rise of serum bilirubin. in such conditions diminutions in 
values of  serum bilirubin to five mg per dL per hour or eighty five µmol 
per Litre per hour have been documented. 
 
 
 A gadget used to calculate the amount of irradiance delivered through the 
device that was used should be made prepared at hand wherever 
phototherapy is given as a means of treatment (Eggert P, Stick C, 
Schroeder H 1984). 
 Each time phototherapy is offered and the above mentioned method should 
be used as a means to make the staff concentrate their attentiveness on 
increasing the delivery of energy has been suggested regularly by some 
practitioners. In order to deliver best possible efficiency this helps us to 
construct phototherapy set-up. 
 As the levels of  serum bilirubin descends to twenty five – thirty µmol/L 
(two-three mg/dL) less than the level which caused the commencement of 
phototherapy, phototherapy is terminated.This is the usual practice( Bell et 
al ., 2006 ) . 
 Later when the management with phototherapy have been stopped, 
following up tests ought to be done in 6 to 12 hours subsequent to stoppage 
of treatment since there could be rebounding in the levels of serum 
bilirubin ( Medhat 2006). In general phototherapy could have no severe 
long-term complications in neonates and it  is much safer. 
 Complications and adverse effects are given below ;  
 Within a NICU environment, neonates those who are rendered elevated 
intensity of ambient luminosity had an enhanced hazard of retinopathy.  
 Therefore, enveloping the infant’s eyes exposed to phototherapy using eye 
patches has been regularly done. 
 
 
 In case the eye patches slide down and making the eyes exposed or blocks 
one or both nares immediate action should be taken . 
 DNA-strand rupture and other complications can occur on genetic material 
by the combined action phototherapy and hyperbilirubinemia .  
 Informations propose insensible water loss might happen,  however  this 
problem is not as significant as it was considered earlier. Augmenting fluid 
intake for  all infants who are under phototherapy has minimised this 
problem . 
 Loose stools can occur in phototherapy. Enhancing fluid supply is must  to 
meet out greater faecal loss of water. 
 Calculation done through assessment of faecal water loss, weight curves, 
specific gravity of urine and urinary output directly shows the fluid volume 
to be supplemented to the needs of that particular infant. 
 During the course of intense phototherapy in certain animal models 
damage of the retina has been noticed ( Ehsanipour et al., 2008). 
 In premature infants who are receiving phototherapy hypocalcemia has been 
found to be more widespread(Xiong T 2011). Changes in melatonin 
metabolism has been proposeed as the cause for this condition (Eghbalian 
and Monsef, 2002). 
 Accidents like burns had been noted due to failure of substitution of UV 
filters. Hence equipment should be maintained regularly 
 Some amino acids in solutions of total parenteral nutrition which are 
subjected to phototherapy may undergo deterioration in their 
 
 
concentrations. So as much as possible total parenteral nutrition solutions 
must be shielded from light. 
 In modern servocontrolled incubators increase of blood flow in skin is less 
pronounced however this effect is increased during phototherapy. In small 
premature infants blood flow redistribution might occur.  
 Due to  the above conditions an augmented occurrence of patent ductus 
arteriosus (PDA) is accounted. The suitable treatment of PDA has been 
reassessed (Fanaroff A 2010).  
 For treating conjugated hyperbilirubinaemia phototherapy is not 
generally used as this does not produce kernicterus . 
Exchange transfusion 
              Whenever there are signs suggestive of acute bilirubin encephalopathy in 
the cases even if total serum bilirubin is falling to lower levels or if there occurs 
major concerns of neurotoxicity exchange transfusion should be thought about 
and predicted. 
Through an umbilical artery or vein exchange transfusion is made. Cause, 
gestational age of the baby, clinical well-being, rate of increase in bilirubin are the 
indications for the usage of exchange transfusion .  
Suggestions as given by the National Institute for Health Care along with 
Excellence (NICE): 
 Indication on behalf of the need for exchange transfusion depends on 
total serum bilirubin level which is at or more than the threshold level  
 
 
 In order to treat babies double-volume exchange transfusion which is the 
procedure of eliminating twice the estimated volume of total blood and 
restoring can be used. 
DO’s and DON’T s 
 At the time of  exchange transfusion do not: 
 administration of intravenous calcium regularly  
 albumin priming to be used. 
 single-volume exchange being carried out  
 continuous multiple phototherapy stoppage 
 After exchange transfusion: 
 Should sustain continuous multiple phototherapy. 
 Treating in concordance with threshold table and management 
threshold graphs after analysing level of serum bilirubin within a 
period of two hours.           
Neonatal problems like electrolyte and calcium imbalance, apnea, catheter 
linked complications, infection, complications associated with the usage of blood 
products, thrombocytopenia, risk of necrotizing enterocolitis, anemia and 
hemorrhage are the side effects of using exchange transfusion (Owa and 
Ogunleni 2009). 
             Sick infants exchange transfusion undergoing are possible to suffer from 
the danger of neonatal mortality ( Jackson JC 1997). 
 
 
 
 
CALCIUM 
In the human body calcium is the most copious trace element. It is present 
in the volume of one and a half  kilograms in average adult male and one kilogram 
in a woman . The bones and teeth comprise 99% of the body calcium. It is in the 
cell membrane and also in the cell, lymph, blood and other body fluids the rest of 
the calcium is present. 
In three fractions or forms calcium in serum or plasma occurs :   
1. The physiologically active form is free or ionized calcium which is present in 
the range of fifty percent –sixty percent of the total concentration of calcium. 
2. One-third of the total serum concentration of calcium is Protein-bound 
calcium. It is not of usage to the tissues as it cannot spread through membranes  
( John P. Cloherty )  
3. Ten percent of the total concentration of calcium is bound or chelated. 
Calcium is complexed to bicarbonate,  sulphate,  phosphate, lactate and citrate. 
 Normal plasma contains 9-11 mg of calcium per 100 ml.  
 In order to have essential health it is important to maintain exact amount of 
the calcium ion in extracellular fluids. To sustain a steady concentration of 
calcium, regardless of changes in intake and excretion three major 
hormones  parathormone, calcitonin and vitamin D3 play a major role. 
 Glucagon, thyroxine, adrenal corticosteroids, estrogens and somatotropin 
are the additional hormones which may also have a role in maintaining  of 
the calcium level (Venkatraman S 1987) . 
 
 
 Calcium has an imperative role in neural excitability, blood coagulation, 
contraction of muscle, release of hormone, activity of enzyme, membrane 
permeability, second messengers. An indispensable structural constituent 
of the skeleton is calcium ion . 
 Calcium salts that are not soluble like phytates, phosphates, oxalates and 
fats which are not degradable are built by the substances that prevent the 
absorption of calcium. Calcium ingested in diet mostly does not gets 
absorbed and is being eliminated through the faeces. 
 Twenty five  to fifty percent of the calcium which is consumed is being 
absorbed by average adult body. A protein produced in reaction in the 
direction of the activity of 1,25-dihydroxyvitamin - D3 or1,25-
dihydroxycholecalciferol helps in  absorption from the duodenum and 
proximal jejunum after binding with calcium  (Kanis JA 1978) . 
Fetal mineral metabolism : (Tsang R C 1992) 
 It has been exclusively modified to get through the particular needs of this 
intra uterine growth period.  
 The fetus gains eighty percent of the needed thirty gram of calcium in the 
last trimester of gestation hence Mineralization of bones happens quickly 
in late months of gestation (Seki K et al 1991). 
 To sustain levels of other minerals and calcium extracellularly so that it is 
physiologically being suitable for tissues of the fetus.  
  To supply adequate calcium and other minerals so as to fully mineralize 
the skeleton prior to birth fully. 
 
 
 A fetus has a considerably elevated concentration of ionized and total 
calcium when compared to the level in the mother in late gestation which 
is a constant finding in the fetus (Givens MH, Macy IG 1993). 
 Likewise, serum phosphate is notably high and serum magnesium is 
slightly raised more than the concentration in the maternal blood. 
 Placental Mineral Ion Transport   
In the later months of gestation massive transfer of calcium and other 
mineral occurs through the  placenta at a speedy rate (Pikin RM 1985). for 
the fetal needs to be fulfilled active placental  transport of phosphate, 
calcium and magnesium is obligatory (Lester GE1986). 
NEONATE 
 A quick modification in regulating mineral homeostasis happens for hours 
to days after cutting the umbilical cord and abruptly losing the placental 
transfer of calcium and placental supply of  Parathyroid hormone related 
peptide ( John P Cloherty). 
 Skeletal calcium stores, dietary calcium intake, vitamin D status,the 
parathormone secretion and renal calcium reabsorption determine the 
levels of serum calcium in newborns following birth(Bergman L 1972). 
 Taking place in the day two of life in the healthy term babies calcium 
levels start to decline and attains a level of seven and a half to eight and a 
half mg/dL subsequent to delivery (David L, Anast CS 1974). 
 End organ unresponsiveness to parathyroid hormone, hypoparathyroidism, 
hypercalcitonemia which comes about through 12 to 24 hours of age, 
 
 
abnormalities of vitamin D metabolism, hypomagnesemia and 
hyperphosphatemia are responsible for the fall in level of serum calcium 
postnataly ( Holick MF et al., 1983). 
 Levels of parathormone raise slowly during the initial 48 hours of living 
and get back to standard serum calcium values are typically on their third 
day of life. 
 For each one g/dL drop in the concentration of plasma albumin the plasma 
calcium decreases by 0.8 mg/dL . 
 The effectiveness of the intestinal calcium absorption and renal handling 
get developed by two to four weeks (Haeney RP et al 1975). The 
augmented threat of hypocalcemia commencing earlier occuring in 
neonates who are in higher risk is due to this transitional phase. 
HYPOCALCEMIA 
By Definition 
               Level of total serum calcium below 1.75 mmol/L that is seven mg/dL or 
ionized calcium below 1 mmol/L which is 4 mg/dL in case of  infants being 
preterm. Level of serum calcium total below 2 mmol/L which is eight mg per dL 
or ionized calcium below 1.2 mmol/L in term neonates is the definition proposed 
for hypocalcemia . 
 
Neonatal hypocalcemia - Early onset type (ENH)  
             This condition is seen commonly and occurs around the initial three to  
 
 
 
four days of life. It happens in clinical situations given below: 
• Infant of Diabetic mother 
• Prematurity 
• Perinatal stress or asphyxia 
• Preeclampsia 
• Iatrogenic (lipid infusions, alkalosis, diuretics, use of blood products, 
phototherapy) 
• Hyperparathyroidism in mother (Drake TS 1986) 
• intake of anticonvulsants  by the mother(phenobarbitone,  phenytoin 
sodium) 
Risk neonates for whom screening is suggested is given below ( Koo WWK, 
1989). 
1. Infants who are born following harsh perinatal asphyxia and having score  of 
Apgar  below four by first minute after birth. 
2. Preterm infants who were born prior to 32 weeks  
3. Infants born to diabetic mothers those who were on intravenous fluids. 
Scheduled time for screening  in risk babies – 
At twenty four and forty eight hours of age  
Clinically  presenting as :  
1. Early onset neonatal hypocalcemia is frequently asymptomatic when 
compared tothe late onset type and it is accidentally identified . 
 
 
 
 
2. If by chance the neonate becomes symptomatic:  
   The symptoms include  
 exaggeration of  startle reflex 
 irritability of neuromuscular system  
 convulsions 
 jitteriness 
 Cardiac association in the form of - decreased contractibility, tachycardia, 
prolonged QT interval, heart failure .  
 Usually the symptoms are non-specific and not connected to its severity. 
Other symptoms include laryngospasm, tachypnoea, cyanosis, apnea and 
vomiting (De Marini, S., et al 1997). 
Hypocalcemia of early onset can be treated as follows : 
(Nine mg of elemental calcium is obtained from one ml of calcium 
gluconate (ten percent)) 
1. Prophylactic for neonates who are at greater risk of hypocalcemia : 
 Four ml/kg/day of ten percent calcium gluconate or forty mg/kg/day of 
elemental calcium  
 Treatment should be maintained for three days. 
2. Based on screening neonates identified to be having asymptomatic 
hypocalcemia :  
• Eight ml/kg/day of ten percent calcium gluconate or eighty mg/kg/day 
elemental calcium or for a period of forty eight hours. 
 
 
• This may be lessened to fifty percent dose for an additional twenty four 
hours and then it should be stopped.  
3. Neonates who were diagnosed to be having symptomatic hypocalcemia: 
 This group of neonates should be given a bolus dosage of two ml/kg/dose 
to be diluted with five percent dextrose in the ratio of 1:1 for a period of 
ten minutes with strict cardiac surveillance. 
 Calcium chloride twenty mg/kg shall be provided by a central line for a 
time period of ten to thirty minutes in case of severe hypocalcaemia with 
reduced cardiac functioning. 
 This procedure has to be continued with an uninterrupted intravenous 
infusion of eighty mg/kg/day calcium in elemental form for a period of 48 
hours.  
 Infusion given continuously is ideal when compared to intravenous bolus 
doses at the rate of 1 ml/kg/dose every sixth hourly.  
 Infusion of calcium should be brought down to fifty percent for the 
subsequent 24 hours of the original dosage later terminated. 
 The infusion possibly can be substituted by managing with calcium orally 
scheduled the final day. 
 All groups of hypocalcemia must be treated for a minimum of seventy two 
hours. Symptomatic hypocalcemia be supposed to be taken care of with a 
flow of continuous infusion for 48 hours period.  
 Standard calcium levels must have been recognized by forty eight hours 
prior to stopping the infusion (Tricia Lacy Gomella). 
 
 
Neonatal hypocalcemia - Late onset vareity (LNH) 
• This situation is uncommon when compared with early onset neonatal 
hypocalcemia .  
• The condition is frequently symptomatic presenting as convulsions or 
neonatal tetany (Bancroft JD1986). 
• This more often appears by the finish around the earliest week of living.  
Hypocalcemia - Late Onset  type is caused by  : 
• Hypomagnesemia (Mimouni F 1994) 
• Increased phosphate load - renal insufficiency, cow milk 
• Parathormone resistance -Transient neonatal pseudohypoparathyroidism 
     •   Iatrogenic  -  Bicarbonate therapy 
 Diuretics (loop diuretics) 
 Citrated blood products 
 Lipid infusions 
 Alkalosis 
 Phototherapy  
 Glucocorticosteriods 
 Phosphate therapy 
   •   Deficiency of vitamin D - Hepatobiliary disease  
 Renal insufficiency                                        
 Malabsorption 
 Maternal vitamin D deficiency 
 
 
   •    Hypoparathyroidism –(i) Primary - parathyroid glands aplasia -  (Di 
George’s syndrome), CATCH 22 syndrome (hypocalcaemia with removal of 
chromosome 22, cardiac anomaly,  thymic aplasia, abnormal  facies, cleft palate),  
Hypoplasia. 
                                           (ii) Secondary - Maternal hyperparathyroidism 
   •    Metabolic Syndromes - Kenny-caffey syndrome  
 Long-chain fatty acyl CoA dehydrogenase deficiency  
 Kearns-sayre syndrome                                 
Treatment of  Late Onset Hypocalcemia : 
1. Hypoparathyroidism  
  Additional supplementation with 1,25(OH)2 Vitamin D3 in the dose of 
0.5-1 μg per day and calcium given as fifty mg/kg/day in three divided dosages is 
given in these neonates.  
2. Vitamin D deficiency states: 
 They do good to as of supplementation  of Vitamin D3 in dosage of 30-60 
ng per kg  per day. 
3. Hypomagnesemia:  
The infant should be given 2 dosage containing 0.2 ml/kg of fifty percent 
magnesium sulphate injection, separated by  twelve hours deep intra muscularly. 
Subsequently  maintenance  dosage  with 0.2 ml/kg/day having 50% magnesium 
sulphate per oral for 3 days.  
 
 
 
 
4. Elevated phosphate load:  
 Avoidance of gels which bind with phosphate . 
 Exclusive breast-feeding must be promoted and discouragement  should be 
done for feeding with cow’s milk.  
HYPERCALCEMIA 
When ionized calcium increases beyond limit of normal which is 5.4 mg/dl 
or 1.35 mmol/l in association with or in the absence of an increase in total calcium 
more than 2.7 mmol per litre or 10.8 mg per dl it is defined as hypercalcemia 
(Mimouni F 1994). 
Hypercalcemia may be caused by : 
a) Hyperparathyroidism 
b) Secondary hyperparathyroidism  
c) Neonatal severe hyperparathyroidism 
d) Familial hypocalciuric hypercalcemia  
e) Iatrogenic by calcium salts 
f) Parathormone related peptide - tumour  
g) Vitamin D intoxication 
h) Idiopathic infantile hypercalcemia 
i) William’s syndrome 
j) Parathormone receptor mutation – Jansen’s metaphyseal chondrodysplasia 
k) Subcutaneous fat necrosis 
l) Parathyroid related 
m) Granulomatous diseases 
 
 
      n) Miscellaneous -  Blue-diaper syndrome 
                                    - Idiopathic infantile hypercalcemia  
                                    -Hypophosphatasia  
                                   - medications – hydrochlorothiazide 
                                   - Hypophosphatemia 
                                  - Vitamin A intoxication 
Treatment of hypercalcemia 
The therapy has four main goals: (De Marini, S., et al 1997) 
 a) By inhibiting intestinal absorption or resorption of bone  
 b) Management of the primary cause    
 c) Dehydration to be corrected 
 d) Urinary calcium excretion needed to be improved  
In conditions existing between moderate and severe hypercalcemia :  
• Extracellular fluid compartment increase by150–250 ml per kg per 24 
hours intravenously with  normal saline would assist to promote excretion 
of calcium.  
• Afterwards infusing furosemide in the rate of 0.5–1.0 mg per kg by 
intravenous manner each sixth hourly will additionally support calciuresis.  
• It is vital to make certain to continue sufficient hydration throughout this 
therapy.  
 
 
 
 
 
Specific therapies : 
a) Subcutaneous giving calcitonin each sixth hourly at a dosage of four to 
eight IU per kg and this should be started immediately. This will 
quickly diminish the serum calcium.  
b) In conditions of  severe and unalleviated hypercalcemia and when the 
newborn is hemodynamically stable hemodialysis can be given. 
Peritoneal dialysis can also be arranged using low-calcium dialysate. 
Supplemental phosphorous in the oral form or intravenous infusion can 
be given to neonates who were treated with peritonal dialysis  (Tricia 
Lacy Gomella) .                                  
c) Glucocorticoids given in elevated dose will lessen the calcium 
absorption in the gut and would lower bone resorption. 
Methylprednisolone (1mg/kg per 24th hourly intravenously), 
hydrocortisone (1mg/kg intravenously every 6th hourly) or its 
equivalent is effective.  
d) Biphosphonate treatment is made use in children and also for adults in 
conditions of vitamin D intoxication and parathormone-mediated 
hypercalcemia.  
Therapy given chronically:  
A diet which is less in vitamin D and calcium is  the basis of management 
in newborns who need therapy for more days. 
 
 
 
 
                                      MATERIALS AND METHODS 
PLACE OF STUDY 
 In the Paediatric Department this study was being conducted, Government 
Rajaji Hospital in co-ordination with the Institute of Physiology, Madurai Medical 
College, Madurai for a period of one year. 
COLLABORATION DEPARTMENT 
 Department of Biochemistry, Madurai Medical College, Madurai. 
ETHICAL COMMITTEE 
 Approval obtained from the ethical committee of Government Rajaji 
Hospital, Madurai. 
STUDY DESIGN 
 Prospective  study 
SAMPLE SIZE 
This study is done in 50 term neonates  in postnatal ward, Government  
Rajaji  Hospital  with unconjugated  hyperbilirubinemia  receiving  phototherapy  
for jaundice. 
Control group consists of blood samples of the neonates in which serum 
electrolytes and bilirubin were measured  before  the onset of phototherapy.   
Study group consists of blood samples of the neonates  in which serum 
electrolytes   and bilirubin were measured after  48 hours of phototherapy. 
Inclusion criteria :  
Term neonates with indirect hyperbilirubinemia which includes 
                      1. Cephalohematoma 
 
 
                      2. Physiological jaundice  
                      3. Idiopathic 
                      4. Large for gestational age 
                      5. Breast feeding jaundice                       
                      6. External bruising 
                      7. Breast milk jaundice  
Exclusion criteria :  
          1. Neonatal asphyxia.                 
         2. Preterm infants. 
         3. Infants of diabetic mothers. 
                   4. Infants undergoing exchange transfusion. 
                   5. Direct hyperbilirubinemia. 
                   6. Hemolytic anaemia/ Rh /ABO incompatability  
                  7. Sepsis. 
                  8. Congenital malformations. 
                  9. Respiratory distress. 
MATERIALS USED FOR STUDY 
1. Proforma – to record the anthropometric measurements and the clinical 
findings of the subjects. 
2. Weighing machine – to record the body weight in kilograms. 
3. Inch tape – to   measure   the  height, head circumference in centimeters. 
 
 
 
 
METHODOLOGY: 
          The study was initiated with the approval of Institutional ethical committee, 
Madurai Medical College, Madurai and was carried out after explaining the 
procedures in detail and getting written informed consent from the subject’s 
mother. 
The experimental protocol includes 
1) Recording a detailed history including mode of delivery, intranatal  
history, immediate postnatal history, maternal history, history of 
phototherapy in sibling, death of sibling due to hypocalcemia, family 
history of seizure disorders and congenital anomalies (as given by the 
subject’s mother) .  
2) Measurement  of  Anthropometric Indices:   
The following were measured: 
 Weight (in kilograms) was recorded using a standard weighing machine. 
 Height, Head circumference (in centimeters) were measured using a  inch 
tape.  
 Head to foot examination was done. Icterus, skin changes, anaemia, 
congenital anomalies were noted  and documented. 
Blood investigations: 
The investigations include indirect bilirubin measured by Diazo method, 
Serum Calcium measured by Arsenazo III method, Serum electrolytes sodium, 
potassium, chloride, bicarbonate measured by  Ion selective electrodes   analyser . 
 
 
Blood specimens were obtained primarily by heel punctures. The 
minimally dangerous method to collect blood samples of neonate’s is the heel 
puncturing method . Merely micro amount of serum or plasma is needed for 
several tests by the analyzers used in new clinical laboratories.  
In the heparinized capillary tubes small amounts are easily obtained by 
heel puncture technique. The deepness of heel pricks must not go beyond 2.4 mm 
and must be done carefully to prevent underlying bone injury. 
Estimation of Serum Bilirubin  
Method : Diazo method  (Van den Bergh 1918) 
The Principle of the test:  
• Bilirubin is changed to azobilirubin molecules when it is treated along 
diazotized sulfanilic acid  otherwise called as Ehrlich's Reagent. There is 
formation in the acid of red purplish colour; the strength within that colour 
is interpreted colorimetrically .  
• Purple azobilirubins are formed by conjugated as well as unconjugated 
bilirubins with diazotized acid.  
• Unconjugated needs an accelerator or solubiliser like methanol but 
conjugated bilirubin can respond to aqueous solution 67 which is known as 
Direct Reaction. 
Name of the reagents used :  
1. Methanol  2.Diazo reagent : Solution A  consisting 15ml of concentrated 
Hydrochloric acid per litre in addition to 1gram of sulphanilic acid within 
water. Solution B consisting in per 100ml 0.5gram of sodium nitrite within 
 
 
water. Make freshly before use blending 10ml of solution A and 0.3ml of 
solution B. 
2. Diazo Blank : fifteen ml of concentrated Hydrochloric acid per litre mixed 
in water.  
3. Bilirubin standard : Ten mg of bilirubin to be dissolved  in a smallest 
amount (about 5ml) of 0.1N solution of sodium, immediately because it is 
not stable in a solution kept in alkaline medium and build a quantity by 
human citrated plasma . 
• In order to destroy the bilirubin which is present plasma has to be left in 
sunlight for few hours prior to use. Since methanol might restore plasma 
needed to make the volume it should be kept ice-covered in little fractions. 
The procedure of the test :The test to be carried out after labelling the test-tubes:  
The Reagent 
used 
Standard used in test  Total serum 
Bilirubin 
Conjugated bilirubin 
 Standard Standard 
control 
Total 
bilirubin 
Total 
bilirubin 
Control 
Conjugated 
bilirubin 
Conjugated  
bilirubin 
control 
Serum 
 
      -      -   0.2 ml    0.2 ml    0.2 ml     0.2 ml 
Standard 
solution10mg/
dl 
 0.2 ml  0.2 ml  
     - 
 
        - 
 
        - 
 
        - 
Distilled water 
 
1.8 ml 1.8 ml   1.8 ml    1.8 ml    4.3 ml      4.3 ml 
Diazo reagent 
 
0.5 ml     -   0.5 ml          -     0.5 ml        - 
Diazo blank 
 
     -  0.5 ml      -     0.5 ml           -       0.5 ml 
Methanol 
 
2.5 ml 2.5 ml   2.5 ml    2.5 ml          -        - 
 
 
Permit to position in dark for a period of 30 minutes and mix . After 10 
minutes interpret absorbance next to 540 nm with usage of  distilled water like 
blank. 
Calculated as follows :  
Total  
bilirubin=    Total-Total control            x   Amount of standard  x         100 
 (mg/dl)     Standard-Standard control                 Volume of serum 
 
Conjugated 
bilirubin= Conjugated-Conjugated control  x  Amount of standard  x  100 
 (mg/dl)     Standard-Standard control                  Volume of serum 
 
Through reducing the level obtained for conjugated bilirubin as of the 
value of total bilirubin value of unconjugated bilirubin in serum could be 
obtained. 
 Bilirubin value in serum  in a newborn : 
 Upto 5 mg / dl is normal . 
Estimation of Serum Calcium 
Method : Arsenazo III method 
The principle for doing the test:  
Arsenazo combining with  
      Alkaline Calcium                 →     Complex of  Calcium-Arsenazo  
                                                               (purplish in colour) 
 
 
A purplish tinted complex that takes up at 650 nm is formed when calcium 
act in response with Arsenazo III within a medium that is faintly alkaline. The 
concentration of calcium is proportionate to the strength of the colour . 
Reagents used 
Calcium reagent used: Buffer, arsenazo III more than or equal to 0.15mM, 
surfactant, eight hydroxyquinoline sulfonate five mM . 
 Procedure which is done 
a. Test tubes labelled as “control”,  “standard”, “sample”,  “reagent blank”. 
b. Within every tube pipetting of 1.0 ml reagent is done . 
c. Into the relevant tubes 0.010 ml or 10ul of the sample is added. Allow it to 
stand at the room temperature  as a minimum of one minute after being  
mixed. 
d. Along with the reagent blank at a wavelength of 650 nm adjustment of  
spectrophotometer for zero is done . 
e. Absorbances of every test tube is interpretted and documented. 
Calculation: 
Absorbance made by sample x Concentration of the Standard = Calcium in mg  
per dl  
Absorbance made by the standard 
 
Normal value of serum calcium : 
Newborns:  8.5 -10.5 mg/dl 
 
 
 
 
 
Estimation of Serum Electrolytes   
Method :  Ion selective electrodes analyser . 
Introduction  about the method:    
• The anions studied are chloride and bicarbonate.  
• The major cations of clinical value are sodium along with potassium . 
• Sulphate, organic acids,  calcium, proteins,  magnesium and phosphate are 
the other electrolytes which are present in serum 
An association exists between the principal ions which could be considered 
after allowance is applied for those ions:-  
(sodium ion + potassium ion ) – (chloride ion + bicarbonate ion ) = 16 ± 2 
Apart from conditions in which there is keen and fast variations in the amount 
of any one of the ions present in the equation given over the correlation is 
appropriate in many clinical situations and also if foremost modifications take 
place in  the concentration of  further ions present in the serum .  
• For assessment of electrolytes in laboratory the above mentioned  
relationship is a suitable confirmation . 
• Principle                                                                                                                                                                                                                           
Two electrodes are used in the analysis.  
 One electrode contains a known concentration of the ion to be 
measured and is called the reference electrode.  
 The other electrode which is responsive only to the ion being measured, 
is exposed to the unknown solution.                                                                                                                   
 
 
 The difference between the concentration of the ion in the reference 
electrode and the ions in the unknown solution causes an electrical 
potential to develop.  
 This potential across the membrane in the electrode is proportional to 
the difference between the two concentrations.  
 A microprocessor converts this voltage into a number representing the 
concentration of the ion in the unknown solution.      
Procedure: 
 To determine levels of potassium, sodium, chlorides and bicarbonates 
particular electrodes are being used.  
 Membrane that is ion selective which would divide a solution of 
identified movement from that of  identifying system is needed .  
 The membrane contains unique glass substance, plate of crystalline 
substance otherwise sometimes an organic ion substituter which would 
saturate a solvent incapable of being mixed with water that is detained 
in a plastic or gel.     
 Changes in concentration of sodium ion are sensed by the sodium 
electrode and changes in concentration of potassium ion are sensed 
through the  potassium electrode .                                                                                                                                            
Normal values of  serum electrolytes :     
  Potassium      :   3.5 – 4.5 mEq / L  
  Bicarbonate  :    22- 28 mEq / L    
  Chloride        :   95 – 105 mEq / L                                                                                                         
  Sodium          :  135 - 145 mEq / L                                                                                                                                                                           
 
 
RESULTS AND OBSERVATION 
The electrolyte changes in term neonates receiving phototherapy for 
jaundice was analysed (serum calcium, sodium, potassium, chloride and 
bicarbonate) before and after phototherapy using  Paired t test.  By means of 
SPSS (Statistical Package for Social Sciences) software version 16, analysis of 
statistics was performed.  
The statistical significance was drawn at ‘p’ value < 0.05.  
 
TABLE-1      
Distribution of neonates according to age in days (N=50) 
 
Age 
(in days) 
Number Percent (%) Cumulative (%) 
4 7 14 14 
5 13 26 40 
6 15 30 70 
7 15 30 100 
Total 50 100.00  
 
 
 
  
 
 
TABLE-2 
Distribution of neonates according to gender (N=50) 
 
Gender Frequency Percent (%) 
MALE 26 52 
FEMALE 24 48 
TOTAL 50 100 
 
Comments:  
Majority of the neonates (52%) were males. 
 
TABLE-3  
Descriptive statistics of anthropometric measurements (N=50) 
 
Measures 
Weight 
(kg) 
Length 
(cms) 
Mean 3.16 51.18 
Standard 
Deviation 
0.405 1.024 
 
 
 
 
 
 
 
TABLE-4 
Analytical statistics of Total serum bilirubin before and after  
   phototherapy (N=50) 
 
When comparing theTotal serum bilirubin before and after Phototherapy it   
was found that there was statistical significance in the values between them. 
Results analysed using Paired t test showed a statistically significant ‘p’ 
value. 
 
 
 
 
 
 
 
 
 
Measures 
 
Total serum bilirubin (mg/dl) 
  
p value 
 Before Phototherapy 
 
After 
Phototherapy 
 
 
Mean 
 
 
14.04 
 
8.13  
0.001 
(significant) 
 
 
Standard 
Deviation 
 
0.71 
 
 
0.40 
 
 
TABLE-5 
           Analytical statistics of serum calcium before and after  
phototherapy (N=50) 
 
 
Measures 
 
 
Serum calcium(mg/dl) 
 
 
p value 
  
Before 
Phototherapy 
 
After 
Phototherapy 
 
 
Mean 
 
 
9.51 
 
 
8.13 
 
 
0.014 
(significant)  
Standard 
deviation 
 
0.29 
 
 
0.40 
 
When comparing the serum calcium before and after phototherapy it was 
found that there was statistical significance in the values between them. 
Results analysed using Paired t test showed a statistically significant ‘p’ value. 
 
 
 
 
 
 
 
 
 
 
 
TABLE-6  
Analytical statistics of serum sodium before and after   
                    phototherapy  (N=50) 
 
 
Measures 
 
 
Serum sodium (mEq/L) 
 
 
p value 
  
Before 
Phototherapy 
 
After 
Phototherapy 
 
 
Mean 
 
 
141.44 
 
 
140.54 
 
 
0.312 
( not significant)  
Standard 
deviation 
 
1.75 
 
 
1.59 
 
 
When comparing the serum sodium before and after phototherapy it was found 
that there was statistical insignificance in the values between them. Results 
analysed using Paired t test showed a statistically insignificant ‘p’ value. 
 
 
 
 
 
 
 
 
TABLE-7  
Analytical statistics of serum potassium before and after  
      phototherapy(N=50)  
 
When comparing the serum potassium before and after phototherapy it was 
found that there was statistical insignificance in the values between them. Results 
analysed using Paired t test showed a statistically insignificant ‘p’ value. 
 
 
 
 
 
 
 
 
 
 
Measures 
 
Serum potassium (mEq/l) 
 
 
p value 
 
  
Before 
Phototherapy 
 
 
After 
Phototherapy 
 
 
Mean 
 
 
4.030 
 
 
4.020 
 
  0.252 
(not significant) 
 
 
 
Standard 
Deviation 
 
0.40 
 
0.37 
 
 
TABLE-8  
 Analytical statistics of Serum chloride before and after  
        phototherapy   (N=50) 
 
 
When comparing the Serumchloride before and after phototherapy it was 
found that there was statistical insignificance in the values between them. Results 
analysed using Paired t test showed a statistically insignificant ‘p’ value. 
 
 
 
 
 
 
 
 
Measures 
 
Serum chloride (mEq/l) 
 
 
 
 
p value  
Before Phototherapy 
 
 
After Phototherapy 
 
 
Mean 
 
99.32 
 
99.28 
 
0.079(not 
significant) 
 
Standard 
deviation 
 
            3.61 
 
                3.32 
 
 
TABLE-9  
Analytical statistics of serum bicarbonate before and after  
phototherapy (N=50) 
 
 
 
When comparing the serum bicarbonate before and after phototherapy it 
was found that there was statistical insignificance in the values between them. 
Results analysed using Paired t test showed a statistically insignificant ‘p’ 
value. 
 
 
 
Measures 
 
Serum  bicarbonate  (mEq/l) 
 
 
 
 
p value  
Before 
Phototherapy 
 
 
After Phototherapy 
 
 
Mean 
 
24.76 
 
24.60 
 
0.472 
(not significant) 
  
Standard 
deviation 
 
1.66 
 
1.49 
 
 
 Among the six pairs, the mean difference in parameters before and after phototherapy is statistically significant 
 (p value < 0.05) in only the Total bilirubin and Serum calcium pairs. 
 Both the Total bilirubin and Serum calcium tend to decrease after phototherapy among the neonates. 
 
TABLE-10 
Paired Samples Test 
 
 
 
 
            Phototherapy 
Paired Differences 
T df 
P value 
Sig. (2-
tailed) Mean 
Standard 
Deviation 
Standard Error 
Mean 
95% Confidence Interval of 
the Difference  
   Before                    After  Lower Upper 
Pair 1 Bilirubin1  Bilirubin 2 5.9020 0.8294 0.1173 5.6663 6.1377 50.316 49 0.001 
Pair 2 Calcium1  Calcium 2 1.1320 0.1743 0.0247 1.0825 1.1815 45.921 49 0.014 
Pair 3 Sodium1  Sodium 2 0.900 1.693 0.239 0.419 1.381 3.758 49 0.312 
Pair 4 Potassium1  Potassium 2 0.00800 0.04882 0.00690 -0.00588 0.02188 1.159 49 0.252 
Pair 5 Chloride1  Chloride 2 0.740 1.440 0.204 0.331 1.149 3.634 49 0.079 
Pair 6 Bicarbonate1   Bicarbonate 2 0.160 0.548 0.078 0.004 0.316 2.064 49 0.472 
 
 
 
 
 
TABLE-11  
Distribution of neonates according to Hypocalcemia (N=50) 
 
 
Hypocalcemia 
 
Frequency Percent (%) 
PRESENT 
 
30 60 
ABSENT 20 40 
TOTAL 50 100 
 
Inference: 
                 60% of neonates showed hypocalcemia 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
The general atypical physical finding in the initial week of life is neonatal 
hyperbilirubinemia (Stoll and Piazza, 2007). A widespread method for reasons  
of medical, social and economic basis is healthy term newborns being discharged 
much earlier from the hospital subsequent to delivery.  
 
Recent study suggest that neonates who have a post-delivery hospital stay 
below 72 hours are at a considerably larger risk for readmissions compared to the 
neonates those whose stay is above 72 hours.  
 
There is concern regarding early discharge of healthy term newborns due 
to reports of bilirubin induced brain damage resulting in sequelae like kernicterus 
(Maisals, 2006). The need for early detection of hyperbilirubinemia in the early 
discharged newborns from the hospital is therefore important. 
 
Phototherapy has emerged as the most widely used form of treatment 
(Stokowski, 2006). In order to diminish the rigorousness of neonatal 
unconjugated hyperbilirubinemia this is the recent therapy of preference (Bell et 
al., 2006). 
 
 
 
As any treatment has, phototherapy also has its side effects(Ehsanipour et 
al., 2008).   Unlike other side effects a very few studies are currently available 
that depicts the adverse effects of phototherapy on serum electrolytes.  
A few studies in the recent past have stressed on the incidence of 
hypocalcemia following phototherapy. The differential effect of other electrolytes 
with phototherapy has not been studied by other workers except that for Curtis 
MD et al (1989).  
 
The plan of this study was intended to establish the serum electrolyte 
changes in neonates receiving phototherapy for neonatal jaundice. 
 
In this present study we have estimated the serum electrolytes in 50 
jaundiced term neonates before and after phototherapy. We compared the 
occurrence of phototherapy induced electrolyte changes in them. We conducted 
the study for a period of one year. 
 
The study was initiated with the approval of Institutional ethical committee 
and was carried out after explaining the procedures in detail and getting written 
informed consent from the neonate’s mother. 
 
We included neonates with unconjugated hyperbilirubinemia which 
comprises of Physiological jaundice, Cephalohematoma, Breast feeding jaundice, 
External bruising, Breast milk jaundice, Large for gestational age. We excluded 
Neonatal asphyxia, Preterm infants, Infants of diabetic mothers, Infants 
 
 
undergoing exchange transfusion, Direct hyperbilirubinemia,  Hemolytic 
anaemia/Rh/ABO incompatability, Sepsis, Congenital malformations and  
Respiratory distress. 
 
The first table of our study depicts the distribution of neonates according to 
chronological age. Most of the neonates were 6 and 7 days which is similar to 
Taheri PA et al (2013).The second table shows the gender distribution in which 
52% are  male.  
 
           In the third table anthropometric measurements including weight and 
length are shown. The mean ± SD weight of the 50 term neonates is 3.16 ± 0.405 
kg. The mean ± SD  length is 51.18 ± 1.024 cms.  
 
       The mean ± SD of total serum bilirubin before phototherapy was 14.04 ± 0.71 
mg / dl and after phototherapy was 8.13 ± 0.40 mg / dl.  Results analysed using 
paired t test shows a statistically significant p value. 
 
       The mean ± SD of serum calcium before phototherapy was 9.51 ± 0.29mg / dl 
and after phototherapy it was 8.13 ± 0.40 mg / dl. Levels of serum calcium 
decreased significantly after phototherapy when compare to values before 
phototherapy with  p value 0.014.    
 
Romagnoli et al in1979 noticed the the relationship in preterm newborns 
of phototherapy and hypocalcemia. Likewise Bergstromand Hakanson in 1981 
 
 
experimented in newborn rat the same findings. Odell and Gutcher in 1983 
suggested considerable reduction in levels of serum calcium in rats which were 
newborn subsequent to keeping them  in fluorescent daylight.  
Eghbalian et al (2008) in his study found that serum calcium levels 
declined considerably after neonates with hyperbilirubinemia treated with 
phototherapy. 
 
There are  some studies in the past to observe the hypocalcaemic effect of 
phototherapy in jaundiced newborn babies which were done by Bergstrom 
andHakanson in 1981,Tan in1991,  Sethi et al, in 1993. 
 
Calcium is essential for several biochemical activities like enzymatic and 
secretory activity in the cell, coagulation of blood, integrity and function of cell 
membrane and also excitability of neuromuscular system.  
 
There is a enhanced permeability for sodium ions by the cell and 
augmented excitabilityof the cell membrane in hypocalcaemia. Hyperreflexia, 
apnea, seizure, stridor or laryngospasm, increase in extensor tone, jitterness and 
clonus are general signs which may be non-specific. 
 
Sethi et al in 1990 proposed that after phototherapy 75% of term neonates 
begin to build up hypocalcaemia. In the same way Medhat in 2006 belonging to 
Cairo University suggested development of hypocalcaemia in 75% of term 
neonates after phototherapy. 
 
 
 
Sourabh dutta (2001) in his study concluded that 75% of fullterm 
neonates with unconjugated hyperbilirubinemia developed hypocalcemia after 
phototherapy. 
 
A significant drop in level of calcium  was observed after phototherapy  
among 66.6% of the term neonates which was noted by Yadav RK and Rajesh 
KY in 2011.  
 
Taheri PA et al (2013) in his study found decrease in serum calcium level 
in 56% babies after 48 hours of phototherapy. Arora S et al (2014) in her study 
found hypocalcemia in 56% of term neonates after 48 hours of phototherapy. 
 
In our study 60% of term neonates developed decrease in serum calcium 
levels 48 hours after phototherapy. Findings in the present study are in 
concurrence with the studies mentioned above.                      
 
In 1998 Jain et al in his study suggested among fullterm neonates with 
hyperbilirubinemia 30% developed hypocalcemia after 48 hours of phototherapy. 
Karamifar et al (2002) in his study found that prevalance of hypocalcemia was 
8.7% in fullterm neonates after 48 hours of phototherapy for hyperbilirubinemia. 
The observations of both the studies are much lesser when compared to the 
studies mentioned above. 
 
 
 
Hunter and Hakinson in 2004 formulated that secretion of melatonin by 
pineal gland gets inhibited by phototherapy. So effect of corticosterone on bone 
calcium becomes inhibite. During phototherapy level of corticosterone in serum 
decreases due to decrease in melatonin. Thus decreased corticosterone has a effect 
which causes hypocalcemia by a reduction of bone resorption .  
Kim (2001)in his study showed of hypocalcemia was caused due to a 
reduction in parathormone secretion in  jaundiced neonates who were  treated with 
phototherapy. 
In Hooman’s study (2005) the significantly higher level of urinary calcium 
excretion was proposed to be the cause of hypocalcemia in  phototherapy treated 
jaundiced neonates . 
Curtis et al (1989) studied diarrhoea in neonates with jaundice who were 
treated under phototherapy. Drastical  reduction in the uptake of potassium, 
chloride and sodium was shown in the study among neonates who  received 
phototherapy jaundice. 
Dee Beresford and Glenys Conolly in the book Neonatal Intensive Care 
Nursing states that babies under phototherapy can have sodium imbalances due to 
insufficient fluid replacements.  
In our study tables 6 – 9 depicts the analysis among levels of serum 
bicarbonate, sodium, chloride and potassium in jaundiced neonates before and 
after phototherapy. 
 
 
The present study shows no noteworthy alteration in the values of  serum 
bicarbonate, sodium, chloride and potassium in jaundiced neonates after 
phototherapy which is in contrary to the work of Curtis et al.  
Table 10 shows the significant decrease in bilirubin and serum calcium in 
the neonates following phototherapy. Out of the total term neonates who received 
phototherapy 60% of the neonates developed hypocalcemia .  
 
 
CONCLUSION 
 
Substantial reduction in the level serum calcium was seen in newborns 
with icterus which was induced by phototherapy were the observations of current 
study. There was no signs and symptoms suggestive of hypocalcemia which may 
present like convulsions, cyanosis and apnea due to diminished calcium in the 
neonates who received phototherapy. 
Proper monitoring of electrolytes after phototherapy in the neonates can 
prevent dyselectrolytemia and its associated complications. In the newborns who 
were treated with phototherapy level of calcium need to be measured and should 
be treated accordingly.  
Phototherapy induced hypocalcemia was well evident in our study and 
although the signs were not remarkable the reduction might proceed to the 
formation of  threshold needed for producing hypocalcemia . 
Hence we strongly suggest assessment of serum calcium, sodium, 
potassium, chloride, bicarbonate along with routine measurement of serum 
bilirubin in neonates before and after phototherapy. Thus by regular monitoring 
and maintaining normal  serum  electrolyte levels we can avoid the development 
of complications  in icteric neonates receiving phototherapy. 
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                                                    PROFORMA 
Name:                                         Age in days:                                            Sex:  
Duration of phototherapy:                                                                                 
  H/o present  complaints: 
H/o yellowish discoloration of body                                                    
H/o passing high coloured urine                                                                                   
H/o diarrhea, scanty urine                                                                                                                                                                                                           
H/o convulsions                                                                                        
H/o skin rashes                                                                                         
H/o irritability                                                                                            
H/o jitteriness                                                                                     
Mode of delivery: Normal vaginal/LSCS/Forceps                                                                                             
Intra natal history: 
H/o prolonged  labour                                                                                                                              
H/o meconium aspiration 
Immediate Post natal history                                                                                                                                      
H/o prelacteal feed                                                                                                                         
H/o Jaundice at the time of birth                                                             
H/o NICU Admission                                                                                
Breast feeding: Time of initiation 
Maternal history: 
H/o consanguinous marriage                                                                                            
H/o Abortions                                                                                                            
H/o still birth, Intra uterine death 
Past history:                                                                                                                                                                                                                  
   H/o phototherapy in sibling                                                                                                                                                                                                                                    
H/o death of sibling due to hypocalcaemia                                                                             
Family history: 
    H/o seizure disorder                                                                                              
H/o congenital anomalies   
 
 
 
 
General examination 
Length(cm):                         Weight(kg):                   Headcircumference(cm):                                                                                
Head to foot examination 
Icterus                                                                           Skin changes                    
Anaemia                                                                       Congenital anamolies  
Systemic examination 
CARDIOVASCULAR SYSTEM 
RESPIRATORY SYSTEM 
ABDOMEN 
CENTRAL NERVOUS SYSTEM  
Investigations: 
  Haemoglobin( g/dl):                                        Blood grouping, Rh typing: 
  Blood sugar(mg/dl):                                                   
  Serum bilirubin-Total(mg/dl): 
                            - Direct(mg/dl): 
                           - Indirect(mg/dl): 
  Serum calcium(mg/dl):                 
  Serum sodium(mEq/L):                                                                     
  Serum potassium(mEq/L):                                                    
  Serum chloride(mEq/L): 
  Serum bicarbonate(mEq/L): 
  Ultrasound Abdomen                                                                                                                                                       
 
 
 
 
Nehahsp jfty; kw;Wk; xg;Gjy; gbtk; 
,izg;G – 3 
Ma;tplj; jfty; kw;Wk; njhlHG tptuq;fs; 
 kQ;rs; fhkhiyapw;fhf xspf;fjpH rpfpr;ir ngWk; epiwkhj gr;rpsk; 
Foe;ijfspd; ,uj;jj;jpd; ePHj;j gFjpapy; cs;s kpd;gF nfhUs; 
khWjy;fis gw;wpa Ma;T. 
 ,e;jg; gf;fj;ij ifnahg;gkpLtjd; %ykhf> gpd;tUtdtw;iw ehd; 
cWjp nra;fpNwd;. 
 Nkw;gb Ma;tpw;fhd [dthp 2015 Njjpaplg;gl;l ,e;j Nehahspj; 
jfty; kw;Wk; xg;Gjy; gbtj;jpYs;s midj;Jj; jfty;fisAk; 
ehd; gbj;Jg; ghpe;J nfhz;bUf;fpNwd; vdTk;> mijg; gw;wp rpe;jpf;f 
vdf;F fhy mtfhrk; ,Ue;jJ vdTk; ehd; cWjpaspf;fpNwd;. 
 Nfs;tpfs; Nfl;gjw;fhd tha;g;G vdf;F ,Ue;jJ. NkYk; vdJ 
Nfs;tpfs; midj;Jk; vdJ jpUg;jpf;Fj; jf;fthW 
gjpyspf;fg;gl;bUf;fpd;wd. 
 ,e;j Ma;tpy; vd; Foe;ijapd; gq;Nfw;G vd; jd;dhHtk; rhHe;jJ 
vdTk;> gq;Nfw;ig vg;NghJ Ntz;LkhdhYk; vt;tpjf; fhuzKk; 
mspf;fhky;> vd; Foe;ijapd; kUj;J ftdpg;G my;yJ rl;l 
chpikfs; ghjpf;fg;glhky; tpyf;fpf; nfhs;s ehd; Rje;jpukhdtH 
vd;gij ehd; Ghpe;J nfhs;fpNwd;. 
 Ntz;bf; nfhs;sg;gl;lg;gb> Ma;T eilKiwfis gpd;gw;wTk;> 
kw;Wk; kUj;JtH> nrtpypfs;> my;yJ kw;w Copa cWg;gpdHfSf;F 
Njitahd jfty;fis toq;fTk; ehd; jd;dhHtj;Jld; xg;Gf; 
nfhs;fpNwd;. 
 
 
 kUj;Jt Nrhjidapd; epjpAjtpaspf;Fk; epWtdk;> epjpAjtpaspf;Fk; 
epWtdj;jpd; rhHgpy; gzpahw;Wk; kw;wtHfs;> ed;ndwpfs; FO kw;Wk; 
xOq;F Kiw mjpfhhpfs; MfpNahUf;F> jw;Nghija Ma;T 
rk;ge;jkhfTk; juT ghJfhg;G mwpf;ifapy; Fwpg;gpl;lg;gbAk;> vdJ 
Foe;ijapd; MNuhf;fpag; gjpNtLfisg; ghHitapLtjw;F vdJ 
mDkjp Njitg;glhJ vd;gij ehd; Ghpe;J nfhs;fpNwd;. ,e;j 
mZfYf;F ehd; xg;Gf; nfhs;fpNwd;. ,Ue;jhYk;> %d;whk; 
egHfSf;F ntspaplg;gLk; my;yJ gpuRhpf;fg;glk; ve;jnthU 
jfty;fspYk; vdJ Foe;ijapd; milahskhdJ 
ntspg;gLj;jg;glhJ vd;gij ehd; Ghpe;J nfhs;fpNwd;. 
 ,e;j Ma;tpypUe;J vOk; ve;jnthU juT my;yJ KbTfspd; 
cgNahfj;jpidAk;> ,J Nghd;w cgNahfkhdJ juT ghJfhg;G 
mwpf;ifapy; Fwpg;gpl;lg;gb kl;Lkhf cgNahfpf;fg;gLk; gl;rj;jpy; 
mitfisj; jLf;fhkypUf;f ehd; xg;Gf; nfhs;fpNwd;. 
Nkw;fz;l Ma;tpy; vd; Foe;ij gq;nfLf;f ehd; xg;Gf; nfhs;fpNwd;. 
 vdf;fhf itj;Jf; nfhs;tjw;fhf ,e;j Nehahsp jfty; kw;Wk; 
xg;Gjy; gbtj;jpd; xH efiy ehd; ngw;Wf; nfhz;bUf;fpNwd;. 
Nehahsp/rl;lg;G+Htkhf Vw;Wf; nfhs;sf;$ba   Njjp 
gpujpepjpapd; (vy; V MH) ifnahg;gk; 
(my;yJ Nehahsp my;yhjtuhdhy;>  (Nehahsp/vy;VMH) 
jhkhfNt 
ghFghlw;w rhl;rpapd; Kd;dpiyapy;  Njjpapl Ntz;Lk;) 
Nehahsp tha;%ykhf xg;Gjy;  
nfhLj;jpUf;fpwhH vd;gij Fwpg;gjw;fhf 
ngUtpuy; Nuif 
 
 
 
 
ABBREVIATIONS 
 
UDPGT  -     URIDINE DIPHOSPHATE GLUCURONYL TRANSFERASE 
 
 
DAT - DIRECT ANTIGLOBIN TEST 
 
ETCO - END -TIDAL CARBON MONOXIDE IN BREATH 
 
LED -  LIGHT EMITTING DIODE 
 
NICU -  NEONATAL INTENSIVE CARE UNIT 
 
PDA -  PATENT DUCTUS ARTERIOSUS 
 
AAP -  AMERICAN ACADEMY OF PAEDIATRICS 
 
NICE -  NATIONAL INSTITUTE FOR HEALTH AND CARE  
  EXCELLENCE 
 
ENH -      EARLY ONSET NEONATAL HYPOCALCEMIA 
 
LNH -  LATE ONSET NEONATAL HYPOCALCEMIA 
 
SBR - SERUM BILIRUBIN  
 
 
 
 
 
S.No Name 
Age in 
days 
Gender 
Weight 
(kg) 
Length 
(cms) 
Total 
bilirubin 
(mg/dl) 
Serum 
Calcium 
(mg/dl) 
Serum 
Sodium 
(mEq/l) 
Serum 
Potasium 
(mEq/l) 
Serum 
Chloride 
(mEq/l) 
Serum 
Bicarbonate 
(mEq/l) 
1 B/o Jeyanthy 2 F 2.6 52.2 13.1 9.1 139 3.9 95.3 23.66 
2 B/o Deepa 3 M 3.1 50.6 14.5 9.56 139.44 4.6 99.66 26.54 
3 B/o Lakshmi 4 F 3.8 51.1 13.9 9.66 141.3 4.2 100.99 22.99 
4 B/o Jyothy 3 M 2.7 52.1 13.2 9.33 143.6 3.6 96.55 27.65 
5 B/oThamarai 5 M 3.5 52 14.2 9.65 143.66 4.6 104.66 25.65 
6 B/oKalavathy 5 M 3.6 51.6 13.6 9.8 143.88 4 95 24.86 
7 B/oMaharani 3 F 3.6 52.6 13.6 9.4 142.66 4.4 99.56 24.42 
8 B/o Seetha 4 M 3.4 51 14 9.1 139 3.8 97.58 25.88 
9 B/o Gowri 2 F 3.5 52.7 14.1 9.56 141.66 3.6 95.66 25.91 
10 B/o Sathya 3 M 2.6 50 13.5 9.66 142.3 3 99.66 27.94 
11 B/o Jeya 2 F 2.9 51.1 13.6 9.33 143.99 4.4 100.99 23.54 
12 B/o Vimala 3 M 2.7 51.5 13.5 9.65 142.99 3.7 96.55 22 
13 B/o Rajathy 4 F 3.4 50.2 13.1 9.8 139.55 4.7 94 23.58 
14 B/o Vinoda 5 M 3.2 50 14.5 9.4 143 3.9 104.88 23.66 
15 B/o Selvi 3 F 3.4 51 13.9 9.55 140.66 4.6 99.56 26.54 
16 B/o Nagajothi 5 M 3.4 51 14.2 9.15 140.58 4.2 97.58 22.99 
17 B/o Karthika 5 F 3.6 50.2 14.6 9.88 140.99 3.6 96.55 27.65 
18 B/o Abirami 5 M 3.4 52 14.6 9.95 140.59 4.6 104.66 25.65 
19 B/o Mareeshwari 4 F 2.7 52.4 13.6 9.22 139 4 104.88 24.86 
MASTER CHART-BEFORE  PHOTOTHERAPY 
 
 
20 B/o Sakeela 5 M 3.5 52.3 14.9 9.33 139.44 4.4 99.56 24.42 
21 B/o Saranya 2 F 3.6 51 14.1 9.43 141.3 3.8 97.58 25.88 
22 B/o Rajalakshmi 3 M 2.9 52.7 13.5 9.41 143.6 3.6 95.66 25.91 
23 B/o  Valarmathi 4 F 3.4 50.2 13.9 9.6 143.66 3 99.66 27.94 
24 B/o Durgaiyammal 5 M 3.5 51.1 13.5 9.4 143.88 4.4 100.99 23.54 
25 B/o Sakthi 5 F 2.6 51.5 14.3 9.77 142.66 3.7 96.55 27.64 
26 B/o Vimala 3 M 2.9 51.6 14.9 9.95 139 4.7 104.66 23.58 
27 B/o Indhira 4 F 2.7 51 14.1 9.55 141.66 4.7 104.66 23.66 
28 B/o Nithya 5 M 3.4 50.4 13.5 9.1 142.3 3.9 104.88 26.54 
29 B/o Senthamilselvi 3 F 3.2 51.6 13.9 9.5 143.99 4.6 99.56 22.4 
30 B/o Saranya 4 M 3.6 50.6 13.5 9.66 142.99 4.2 97.58 22.4 
31 B/o Indhu preetha 5 F 3.4 50.8 13.1 9.22 139.55 3.6 96.55 25.65 
32 B/o Sengeshwari 2 M 3.5 50.3 14.5 9.84 139 4.6 104.66 24.86 
33 B/o Vijayalakshmi 3 F 3.5 52 13.9 9.67 140.66 4 104.88 24.42 
34 B/o Renuka 4 M 3.6 50.6 14.2 9.64 140.58 4.4 99.56 25.88 
35 B/o Rani 5 F 2.9 50.3 14.6 9.7 141.66 3.8 97.58 25.91 
36 B/o Selva meena 3 M 3.4 51.8 14.6 9.5 142 3.6 95.66 22.4 
37 B/o Sasikala 4 F 3.5 50.2 13.6 9.6 142.6 3 103.5 23.54 
38 B/o Rajeswari 4 M 2.6 52 14.9 9.21 141.66 4.4 96.55 23.8 
39 B/o Lakshmi 2 F 3.6 52 14.2 9.65 142.3 3.7 104.66 22.99 
40 B/o Chithradevi 4 M 3.2 51 13.9 9.2 143.99 4.7 104.88 22.3 
41 B/o Mahalakshmi 2 F 3.4 50.8 13.5 9.33 142.99 4.6 99.56 25.65 
 
 
 
42 B/o Jansi 4 M 3.2 50.1 14.5 9.22 142 4 97.58 24.86 
43 B/o Santhi devi 4 F 3.5 50.6 14.5 9.84 139 4.4 95.66 25.3 
44 B/o Ambiga 3 M 2.5 52 13.9 9.1 141 3.8 94.6 22.58 
45 B/o Sri devi 5 F 2.9 50.3 14.2 9.62 139 3.6 94.66 22.8 
46 B/o Rekha 5 M 2.7 52 14.6 9.52 141 3 103.6 23.5 
47 B/o Latha 4 F 2.5 52 14 9.1 139 4.4 94 23.54 
48 B/o Sangeetha 5 M 2.8 50.4 14.8 9.9 143 3.7 94.6 27.65 
49 B/o Suganya 3 F 2.6 50 14.9 9.64 139 4.7 94.66 25.65 
50 B/o Soniya 4 M 2.5 50 14.2 9.7 141 3.5 103.6 24.86 
 
 
AFTER PHOTOTHERAPY 
 
S. 
No. 
Name 
Age in 
days 
Gender 
Weight 
(Kgs) 
Length 
(cms) 
Total 
bilirubin 
(mg/dl) 
Serum 
calcium 
(mg/dl) 
Serum 
Sodium 
(mEq/l) 
Serum  
Potasium 
(mEq/l) 
Serum 
Chloride 
(mEq/l) 
Serum 
Bicarbonate 
(mEq/l) 
1 B/o Jeyanthy 4 F 2.6 52.2 7.9 7.9 139 3.9 95.3 23.6 
2 B/o Deepa 5 M 3.1 50.6 7.9 8.4 139.44 4.2 99.66 26.5 
3 B/o Lakshmi 6 F 3.8 51.1 8.5 8.6 141.3 3.6 100.99 22.9 
4 B/o Jyothy 5 M 2.7 52.1 8.6 7.9 143.6 4.6 96.55 27.6 
5 B/oThamarai 7 M 3.5 52 7.8 7.9 138 3.4 104.66 25.6 
6 B/oKalavathy 7 M 3.6 51.6 8.6 7.8 138.7 4.2 95 24.8 
7 B/oMaharani 5 F 3.6 52.6 8.2 8.2 142.66 4.5 99.56 24.4 
8 B/o Seetha 6 M 3.4 51 8.4 8.4 139 3.6 97.58 25.8 
9 B/o Gowri 4 F 3.5 52.7 7.7 8.4 138.9 4.4 95.66 25.9 
10 B/o Sathya 5 M 2.6 50 8.4 8.6 142.3 3.9 99.66 27.9 
11 B/o Jeya 4 F 2.9 51.1 7.9 8.1 138 3.9 100.99 23.5 
12 B/o Vimala 5 M 2.7 51.5 7.9 7.9 142.99 4.2 96.55 22 
13 B/o Rajathy 6 F 3.4 50.2 8.5 7.9 139.55 3.6 94 23.5 
14 B/o Vinoda 7 M 3.2 50 8.6 8.7 143 4.6 103.88 23.6 
15 B/o Selvi 5 F 3.4 51 7.8 8.6 140.66 3.4 99.56 26.5 
16 B/o Nagajothi 7 M 3.4 51 8.6 8.5 140.58 4.2 97.58 22.9 
 
 
17 B/o Karthika 7 F 3.6 50.2 8.2 7.9 140.99 4.5 96.55 27.6 
18 B/o Abirami 7 M 3.4 52 8.4 8.7 140.59 3.6 104.66 25.6 
19 B/o Mareeshwari 6 F 2.7 52.4 7.6 8.2 139 3.9 94.5 24.8 
20 B/o Sakeela 7 M 3.5 52.3 8.6 7.9 139.44 4.2 99.56 24.4 
21 B/o Saranya 4 F 3.6 51 8.2 8.4 141.3 3.6 97.58 25.8 
22 B/o Rajalakshmi 5 M 2.9 52.7 8.4 8.6 138.6 4.6 95.66 25.9 
23 B/o  Valarmathi 6 F 3.4 50.2 7.6 8.1 142.5 3.4 99.66 27.9 
24 B/o Durgaiyammal 7 M 3.5 51.1 8.4 7.9 138.6 4.2 100.99 23.5 
25 B/o Sakthi 7 F 2.6 51.5 7.9 8.8 142.66 4.5 96.55 27.6 
26 B/o Vimala 5 M 2.9 51.6 8.8 8.7 139 3.6 94.5 23.5 
27 B/o Indhira 6 F 2.7 51 8.5 8.6 141.66 4.4 104.66 23.6 
28 B/o Nithya 7 M 3.4 50.4 7.7 8.7 142.3 3.9 102.88 26.5 
29 B/o Senthamilselvi 5 F 3.2 51.6 7.8 8.6 143.99 3.9 99.56 22.4 
30 B/o Saranya 6 M 3.6 50.6 8.6 8.6 140.3 4.2 97.58 22.4 
31 B/o Indhu preetha 7 F 3.4 50.8 8.2 8.2 139.55 3.6 96.55 25.2 
32 B/o Sengeshwari 4 M 3.5 50.3 8.4 8.8 139 4.6 104.66 24.2 
33 B/o Vijayalakshmi 5 F 3.5 52 7.6 8.4 140.66 3.4 102.8 24.4 
34 B/o Renuka 6 M 3.6 50.6 8.2 8.6 139.5 4.2 99.5 25.2 
35 B/o Rani 7 F 2.9 50.3 8.4 8.6 140.2 4.5 97.5 25.9 
36 B/o Selva meena 5 M 3.4 51.8 7.6 8.6 138.6 4.2 95.6 22.4 
 
 
 
37 B/o Sasikala 6 F 3.5 50.2 7.8 7.9 142.6 4.5 103.5 23.5 
38 B/o Rajeswari 6 M 2.6 52 7.9 8.7 141.66 3.6 96.55 23.8 
39 B/o Lakshmi 4 F 3.6 52 7.9 8.6 142.3 4.4 104.66 22.9 
40 B/o Chithradevi 6 M 3.2 51 8.5 8.8 138 3.9 102.88 22.3 
41 B/o Mahalakshmi 4 F 3.4 50.8 8.6 7.9 138.7 3.9 99.5 25.6 
42 B/o Jansi 6 M 3.2 50.1 7.8 8.4 143.6 4.2 97.5 24.8 
43 B/o Santhi devi 6 F 3.5 50.6 7.8 8.6 139 3.6 95.6 25.3 
44 B/o Ambiga 5 M 2.5 52 7.9 8.1 143.5 4.6 94.6 22.5 
45 B/o Sri devi 7 F 2.9 50.3 7.9 7.9 138.2 3.4 94.6 22.3 
46 B/o Rekha 7 M 2.7 52 7.5 8.8 139 4.2 102.1 23.5 
47 B/o Latha 6 F 2.5 52 8.6 8.7 139 4.5 94 23.54 
48 B/o Sangeetha 7 M 2.8 50.4 7.8 8.6 143 3.2 94.6 27.6 
49 B/o Suganya 5 F 2.6 50 8.5 8.4 141.5 4.6 94.1 25.2 
50 B/o Soniya 6 M 2.5 50 7.8 8.7 141 3.4 95.6 24.8 
 
 
 
 
 
 
 
 
FIGURE -  1 
 
 
 
 
 
 
 
14% 
26% 
30% 30% 
0 
5 
10 
15 
20 
25 
30 
35 
4 5 6 7 
Age Distribution 
4 
5 
6 
7 
Age of the neonate in days 
p
e
r
c
e
n
t
a
g
e 
 
 
 
FIGURE -  2 
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FIGURE - 3 
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FIGURE - 4 
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FIGURE-5 
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FIGURE - 6 
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FIGURE - 7 
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FIGURE - 8 
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FIGURE - 9 
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RICHARD JOHN CREMER PAEDIATRICIAN 
 
 
 
 
  
 
 
 
 
 
WARD NURSE – ROCHFORD HOSPITAL ENGLAND 
 
 
  
 
 
 
 
 
HEME METABOLISM 
 
 
 
  
 
 
 
 
 
BILIRUBIN METABOLISM 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
ISOMERISATION OF BILIRUBIN TO LUMIRUBIN 
 
 
  
 
 
 
 
 
BILIBLANKET 
 
 
 
 
 
 
 
 
CRITERIAS OF PHOTOTHERAPY 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
PHOTOTHERAPY DONE WITH EYE SHEILDING 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
CALCIUM METABOLISM IN FETUS AND IN NEONATE  
 
 
  
 
 
 
 
 
ARSENAZO III METHOD 
 
 
 
